1
|
Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. Ann Oncol 2014; 25:1442-1447. [PMID: 24723487 DOI: 10.1093/annonc/mdu148] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Prognosis of unresectable glioblastoma (GB) remains poor, despite temozolomide (TMZ)-based chemoradiation. Activity of bevacizumab (BEV) and irinotecan (IRI) has been reported in recurrent disease. We evaluated BEV and IRI as neo-adjuvant and adjuvant treatment combined with TMZ-based chemoradiation for unresectable GB. PATIENTS AND METHODS Patients with unresectable GB, age 18-70, IK ≥50 were eligible. The experimental arm (BEV/IRI) consisted of neo-adjuvant intravenous BEV, 10 mg/kg, and IRI, 125 mg/m(2), every 2 weeks for four cycles before radiotherapy (RT) (60 Gy), concomitant oral TMZ, 75 mg/m(2)/day, and BEV, 10 mg/kg every 2 weeks. Adjuvant BEV and IRI were given every 2 weeks for 6 months. The control arm consisted of concomitant oral TMZ, 75 mg/m(2)/day during RT, and 150-200 mg/m(2) for 5 days every 28 days for 6 months. The use of BEV was allowed at progression in the control arm. RESULTS Patients (120) were included from April 2009 to January 2011. The working hypothesis was that treatment would increase the progression-free survival at 6 month (PFS-6) from 50% to 66%. The primary objective was not achieved, and only 30 out of 60 patients were alive without progression at 6 months (50.0% [IC95% (36.8; 63.1)] in the BEV/IRI arm when 37 out of 60 patients were required according to the Fleming decision rules. PFS-6 was 7.1 months in BEV/IRI versus 5.2 months in the control arm. The median overall survival was not different between the two arms (11.1 months). Main toxicities were three fatal intracranial bleedings, three bile duct or digestive perforations/infections (1 fatal), and six thrombotic episodes in the BEV/IRI arm, whereas there was one intracranial bleeding, two bile duct or digestive perforations/infections (1 fatal), and one thrombotic episode in the control arm. CONCLUSIONS Neo-adjuvant and adjuvant BEV/IRI, combined with TMZ-radiation, is not recommended for further evaluation in the first-line treatment of unresectable GB. CLINICAL TRIAL REGISTRATION Clinical trial registered under EUDRACT number 2008-002775-28 (NCT01022918).
Collapse
Affiliation(s)
- B Chauffert
- Department of Medical Oncology, University Hospital, EA 4666, Amiens.
| | - L Feuvret
- Department of Radiotherapy, Pitie-Salpetriere University Hospital, Paris
| | - F Bonnetain
- Methodology and Quality of Life Unit, Department of Oncology, EA 3181, University Hospital, Besancon
| | | | - D Frappaz
- Department of Oncology, Leon Berard Centre for Fight against Cancer, Lyon
| | - H Taillia
- Department of Neurology, HIA Val de Grace, Paris
| | - R Schott
- Department of Oncology, Paul Strauss Centre for Fight against Cancer, Strasbourg
| | - J Honnorat
- Department of Neurology, University Hospital, Lyon
| | - M Fabbro
- Department of Oncology, Val d'Aurelle Center for Fight against Cancer, Montpellier
| | - I Tennevet
- Department of Oncology, Henri Becquerel Center for Fight against Cancer, Rouen
| | - F Ghiringhelli
- Department of Oncology, GF Leclerc Center for Fight against Cancer, Dijon
| | - J S Guillamo
- Department of Neurology, University Hospital, Caen
| | - X Durando
- Department of Oncology, Jean Perrin Center for Fight against Cancer, Clermont-Ferrand
| | | | - M Frenay
- Department of Oncology, Antoine Lacassagne Center for Fight against Cancer, Nice
| | - C Campello
- Department of Neurology, University Hospital, Nimes
| | - C Dalban
- Methodology Unit, GF Leclerc Center for Fight against Cancer, Dijon
| | - J Skrzypski
- Methodology Unit, GF Leclerc Center for Fight against Cancer, Dijon
| | - O Chinot
- Department of Neuro-Oncology, University Hospital La Timone, Marseille, France
| |
Collapse
|
2
|
Pallud J, Mandonnet E, Fontaine D, Bauchet L, Peruzzi P, Guyotat J, Audureau E, Blonski M, Taillandier L, Frenay M, Baron M, Duffau H, Capelle L. La cinétique tumorale radiologique spontanée prédit la transformation maligne et la survie globale des gliomes diffus de bas grade. Une étude multicentrique de 407 cas. Neurochirurgie 2012. [DOI: 10.1016/j.neuchi.2012.10.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
3
|
Kim JH, Charkravarti A, Wang M, Aldape K, Sulman E, Bredel M, Hegi M, Gilbert M, Curran W, Werner-Wasik M, Mehta M, van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Xuan KH, Chang JH, Oh MC, Kim EH, Kang SG, Cho J, Kim SH, Kim DS, Kim SH, Seo CO, Lee KS, Kim MM, Dabaja BS, Jeffrey Medeiros L, Allen P, Kim S, Fowler N, Peereboom DM, Seidman AD, Tabar V, Weil RJ, Thorsheim HR, Smith QR, Lockman PR, Steeg PS, Mallick S, Joshi N, Gandhi A, Jha P, Suri V, Julka PK, Sarkar C, Sharma D, Rath GK, Blumenthal DT, Talianski A, Fishniak L, Bokstein F, Taal W, Walenkamp AM, Taphoorn MJ, Beerepoot L, Hanse M, Buter J, Honkoop A, Groenewegen G, Boerman D, Jansen RL, van den Berkmortel FW, Brandsma D, Kros JM, Bromberg JE, van Heuvel I, Smits M, van der Holt B, Vernhout R, van den Bent M, Matienzo L, Batara J, Torcuator R, Yovino S, Balmanoukian A, Ye X, Campian J, Hess A, Fuchs E, Grossman SA, Leonard AK, Wolff J, Blanchard M, Laack N, Foote R, Brown P, Pan E, Yu D, Yue B, Potthast L, Smith P, Chowdhary S, Chamberlain M, Rockhill J, Sales L, Halasz L, Stewart R, Phillips M, Mathew M, Ott P, Rush S, Donahue B, Pavlick A, Golfinos J, Parker E, Huang P, Narayana A, Clark S, Carlson JA, Gaspar LE, Ney DE, Chen C, Kavanagh B, Damek DM, Martinez NL, DeAngelis LM, Abrey LE, Omuro A, Zhu JJ, Esquenazi-Levy Y, Friedman ER, Tandon N, Mathew M, Hitchen C, Dewyngaert K, Narayana A. CLIN-MEDICAL + RADIATION THERAPIES. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M, Perin A, Verginelli F, Dali R, Hei Man Fung K, Lo R, Longatti P, Guiot M, Del Maestro RF, Rossi S, Di Porzio U, Stechishin O, Weiss S, Stifani S, Sanzey M, Golebiewska A, Stieber D, Nazarov P, Muller A, Vallar L, Niclou SP, Lawler SE, Chiocca E, Williams SP, Wanka C, Steinbach JP, Rieger J, Lavon I, Zrihan D, Refael M, Siegal T, Sminia P, Van Nifterik KA, Van den Berg J, Lafleur VM, Stalpers LJA, Slotman BJ, Di stefano A, Enciso-Mora V, Marie Y, Desestret V, Labussiere M, Idbaih A, Hoang-Xuan K, Delattre J, Houlston R, Sanson M, Woehrer A, Slavc I, Stefanits H, Waldhoer T, Heinzl H, Zielonke N, Czech T, Hainfellner JA, Haberler C, Zouaoui S, Darlix A, Virion J, Rigau V, Mathieu-Daude H, Bauchet F, Figarella-Branger D, Duffau H, Taillandier L, Bauchet L, Naydenov E, Popov R, Tanova R, Minkin K, De Vleeschouwer S, Van Gool S, Cavaletti G, Wilbers J, Hoebers F, Boogerd W, van Werkhoven E, Nowee M, Hart G, van Dijk E, Kappelle A, Dorresteijn L, Furuse M, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Miyatake S, Boele FW, Heimans JJ, Aaronson NK, Peereboom DM, Sloan AE, Supko JG, Ye X, Rich JN, Prados MD, Ahluwalia M, Grossman SA, Spiegl-Kreinecker S, Loetsch D, Taphoorn MJB, Wild M, Ghanim B, Pirker C, Pichler J, Serge W, Lenz S, Wurm G, Berger W, Tamiya T, Miyake K, Postma TJ, Okada M, Kawai N, Grossi I, Rigakos G, Lampropoulos S, Stavridi F, Tsoulos N, Nasioulas G, Papadopoulou E, Razis E, Reijneveld JC, Schroeteler J, Klosterkemper Y, Schwake M, Stummer W, Ewelt C, Field KM, Rosenthal MA, Wheeler H, Cher L, Hovey E, Klein M, Nowak AK, Brown C, Livingstone A, Sawkins K, Simes J, Linsenmann T, Jawork A, Hagemann C, Kessler AF, Berg F, Habets EJJ, Lohr M, Ernestus RI, Vince GH, Rodriguez FJ, Heaphy CM, Nguyen DN, de Wilde RF, Orr B, Raabe E, Eberhart CG, Taphoorn MJB, Meeker AK, Klein SP, Van Calenbergh F, van Loon J, Menten J, Clement P, De Vleeschouwer S, Goffin J, Lonardi F, Gioga G, Nederend S, Bonometti M, Ferigo L, Buonocore F, Campostrini F, Golebiewska A, Bougnaud S, Stieber D, Brons N, Vallar L, Hertel F, Klein M, Bjerkvig R, Niclou S, Strik HM, Carl B, Kallenberg K, Moiyadi AV, Gupta T, Shetty P, Nair V, Jalali R, Delgadillo D, Compter I, de Kunder SL, Houben RMA, Jager JJ, Bosmans G, Anten MHME, Baumert BG, Duerinck J, Du Four S, Van Binst A, Xuan KH, Everaert H, Michotte A, D'haens J, Neyns B, Basmaci M, Hasturk AE, de Kunder SL, Compter I, Schijns OEMG, ter Laak-Poort MP, Bottomley A, Anten MHME, Jansen RLH, Baumert BG, Happold C, Roth P, Wick W, Schmidt N, Florea A, Reifenberger G, Weller M, Van den Bent MJ, Ho C, Leugner D, Easaw J, Lim G, Rosenberg T, Thomassen M, Jensen S, Larsen M, Sorensen K, Hermansen S, Reijneveld JC, Kruse T, Kristensen B, Pichler J, Hollmuller I, Ghanim B, Spiegl-Kreinecker S, Ursu R, Ferrari D, Bailon O, Augier A, Minaya Flores P, Dubessy A, Banissi C, Belin C, Levy C, Carpentier AF, Boudouresque F, Delphino C, Metellus P, Pirisi V, Figarella-Branger D, Chinot O, Ouafik L, Berthois Y, Nakamura H, Makino K, Hide T, Yano S, Kuratsu J, Stevens GHJ, Ahluwalia M, Hashemi N, Berbis J, Peereboom D, Barnett GH, Wibom C, Ghasimi S, Van Loo P, Brannstrom T, Trygg J, Henriksson R, Bergenheim T, Andersson U, Auquier P, Ryden P, Melin B, Ackerl MS, Flechl B, Dieckmann K, Preusser M, Widhalm G, Sax C, Marosi C, Seliger C, Kumthekar PU, Leukel P, Jachnik B, Bogdahn U, Vollmann A, Hau P, Chung SA, Luk PP, Shen H, Decollogne S, Day BW, Grimm SA, Stringer BW, Hogg PJ, Dilda PJ, McDonald KL, Cernea DR, Pruteanu P, Todor N, Florian S, Bogdan V, Cercea C, Chandler J, Leibetseder A, Ackerl M, Flechl B, Sax C, Widhalm G, Dieckmann K, Preusser M, Marosi C, Torres-Martin M, Pena-Granero C, Helenowski IB, Isla A, Pinto GR, Custodio AC, Melendez B, Castresana JS, Rey JA, Banissi C, Maubant S, Rancic M, Carpentier AF, Marymont M, Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, Kaneva R, Poptodorov G, Mitev V, Gabrovsky N, Rademaker A, Piccirillo SGM, Spiteri I, Sottoriva A, Marko N, Tavare' S, Collins P, Watts C, Fedrigo CA, Da Rocha AB, Stalpers LJA, Wagner L, Baumert BG, Slotman B, Peters GJ, Sminia P, Fernandez M, Gawrisch VJ, Ruttgers M, Jachnik B, Proescholdt M, Bogdahn U, Stell B, Vollmann-Zwerenz A, Hau P, Trevisan E, Magistrello M, Bertero L, Bosa C, Greco Crasto S, Garbossa D, Lolli I, Ruda R, Raizer J, Soffietti R, Ichikawa T, Kurozumi K, Onishi M, Ishida J, Shimazu Y, Fujii K, Inoue S, Chiocca EA, Kaur B, Kumthekar PU, Date I, Dictus C, Friauf S, Valous NA, Muerle B, Unterberg AW, Herold-Mende CC, Caroli M, Di Dristofori A, Lucarella F, Grimm S, Menghetti C, Lanfranchi G, Gaini SM, Duerinck J, Clement P, Bouttens F, Neyns B, D'Hondt L, Gennigens C, Staelens Y, Jacobs DI, Joosens E, Van Fraeyenhove F, Rogiers A, Darlix A, Baumann C, Lorgis V, Blonski M, Chauffert B, Zouaoui S, Beauchesne P, Stell BV, Taillandier L, Vaccaro V, Pace A, Vidiri A, Vari S, Telera S, Giannarelli D, Russillo M, Anelli V, Carapella CM, Rademaker A, Fabi A, Florian SI, Soritau O, Neagoe I, Abrudan C, Tomuleasa C, Cernea D, Petrescu M, Baritchii A, Florian SI, Chandler J, Abrudan C, Baritchii A, Fornara O, Mirza S, Khan Z, Odeberg J, Stragliotto G, Butler L, Soderberg-Naucler C, Soderberg Naucler C, Marymont MH, Stragliotto G, Peredo I, Rahbar A, Lilja A, Taher C, Orrego A, Wolmer Solberg N, Brandes AA, Depenni R, Marcello N, Helenowski IB, Valentini A, Faedi M, Urbini B, Crisi G, Franceschi E, Poggi R, Baruzzi A, Berghauser Pont LME, Kloezeman JJ, French PJ, Wagner L, Dirven CMF, Lamfers MLM, Leenstra SL, Stragliotto G, Bartek J, Hylin S, Peredo I, Rahbar A, Soderberg Naucler C, Dahlrot RH, Raizer JJ, Kristensen BW, Hjelmborg JVB, Herrstedt J, Hansen S, Nittby HC, Persson BRR, Ceberg C, Widegren B, Salford LG, Poulsen HS, Claudel G, Grunnet K, Michaelsen SR, Broholm H, Christensen IJ, Tinchon A, Oberndorfer S, Marosi C, Ruda R, Sax C, Calabek B, Muller C, Grisold W, Bouwens T, Trouw L, Heijsman D, Kremer A, van der Spek P, Dirven C, Lamfers M, Al-Khawaja H, Pollanz S, Colmar K, Tinchon A, Calabek B, Oberndorfer S, Pohnl R, Grisold W, Hong Y, Ko K, Lee E, De Groot M, Choenni EP, Garat E, Sizoo EM, Uitdehaag B, Buter J, Van Linde ME, Postma TJ, Taphoorn MJB, Heimans JJ, Reijneveld JC, Bertero L, Bosa C, Beauchesne P, Trevisan E, Tarenzi L, Garbossa D, Mantovani C, Soffietti R, Ruda R, Lotsch D, Spiegl-Kreinecker S, Pirker C, Hlavaty J, Hassani K, Petznek H, Grusch M, Berger W, Kaloshi G, Spahiu O, Djamandi P, Djamandi P, Ruka M, Haxhihyseni E, Bushati T, Bethune B, Petrela M, Tabatabai G, Felsberg J, Sabel M, Hofer S, Westphal M, Weller M, Reifenberger G, Wertz M, Padovani L, Nguyen-Thi P, Bequet-Boucard C, Barrie M, Matta M, Muracciole X, Chinot O, Timmer M, Rohn G, Goldbrunner R, Thon N, Kreth F, Di Patrizio P, Simon M, Westphal M, Schackert G, Nikkhah G, Tatagiba M, Hentschel B, Weller M, Tonn J, Smrdel U, Fack F, Taillandier L, Zheng L, Frezza C, Keunen O, Kalna G, Nazarov P, Gottlieb E, Niclou SP, Bjerkvig R, Radic J, Murgic J, Sizoo EM, Maric Brozic J, Jazvic M, Soldic Z, Bolanca A, Raizer J, Grimm S, Levy R, Muro K, Rosenow J, Chandler J, Taphoorn MJB, Bredel M, Kalita O, Vaverka M, Hrabalek L, Zlevorova M, Cechakova E, Trojanec R, Kneblova M, Hajduch M, Ehrmann J, Uitdehaag B, Naskhletashvili DR, Gorbounova V, Bychkov M, Bekyashev A, Karakhan V, Aloshin V, Fu R, Moskvina E, Gaziel TB, Poulsen HS, Heimans JJ, Muhic A, Rahbar A, Peredo I, Wolmer Solberg N, Taher C, Dzabic M, Xu X, Skarman P, Tammik C, Stragliotto G, Deliens L, Soderberg-Naucler C, Ahluwalia MS, hashemi-Sadraei N, Barnett GH, Fabbro M, Laigre M, Langlois C, Castan F, Bauchet L, Duffau H, Reijneveld JC, Bonafe A, Spoor JKH, Khorami K, Kloezeman J, Balvers R, Dirven C, Lamfers M, Leenstra S, Spoor JKH, van der Kaaij M, Pasman HW, Kloezeman J, Geurtjens M, Dirven C, Lamfers M, Leenstra S, Trister AD, Neal ML, Cloke T, Baldock AL, Ahn S, Rampling RP, Mrugala MM, Rockhill JK, Rockne R, Swanson KR, Swanson KR, Rockne R, Hawkins-Daarud A, Corwin D, Neal ML, Rockhill JK, James A, Mrugala MM, Rostomily R, Alvord EC, D'Alessandro G, Catalano M, Cipriani R, Chece G, Limatola C, Graham K, Williamson A, Mulholland P, Lamb C, James A, Clark B, Chalmers A, de Kunder SL, Postma AA, Huysentruyt CJR, Dings J, ter Laak-Poort MP, Seystahl K, Peoples S, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A, Janz C, Buhl RM, Jiang T, Darlix A, Al-Salihi O, Virion J, Zouaoui S, Rigau V, Tretarre B, Mandonnet E, Pinelli C, Duffau H, Taillandier L, Bauchet L, Ng H, Twelves C, Yang L, Pang JCS, Roelcke U, Nowosielski M, Bertero L, Crippa F, Hofer S, Bruehlmeier M, Remonda L, Soffietti R, Halford S, Wyss M, Reyes-Botero G, Fiorelli M, Mokhtari K, Delattre J, Laigle-Donadey F, Amelio D, Lorentini S, Giri MG, Meliado G, McGuigan L, Fellin F, Gargano G, Ricciardi GK, Pioli F, Schwarz M, Amichetti M, Ribba B, Kaloshi G, Peyre M, Ricard D, Ritchie J, Tod M, Cartalat-Carel S, Delattre J, Honnorat J, Grenier E, Ducray F, Bastin F, Pirotte B, Bouquey D, Roger T, Sing-Jasuja H, Riva M, Raneri F, Pessina F, Casarotti A, Comi A, Fava E, Papagno C, Bello L, Blonski M, Pallud J, Schumacher T, Goze C, Mandonnet E, Beauchesne P, Baron M, Fontaine D, Darlix A, Duffau H, Taillandier L, Sinclair G, Hylin S, Sahm F, Nordstrom L, Stragliotto G, Mucha-Malecka A, Glinski B, Malecki K, Ahluwalia MS, Robles Irizarry L, Hashemi Sadraei N, Stevens G, Barnett GH, von Deimling A, Mucha-Malecka A, Glinski B, Malecki K, Jarosz M, Dymek P, Chrostowska A, Hetnal M, Miwa T, Oi S, Nonaka Y, Wick W, Sasaki H, Adachi J, Suzuki T, Yanagisawa T, Mishima K, Fukuoka K, Koga T, Matsutani M, Nishikawa R, Burger MC, Platten M, Brucker DP, Baumgarten P, Ronellenfitsch MW, Hasselblatt M, Eccles MR, Klingebiel T, Weller M, Mittelbronn M, Steinbach JP, Walker DA, Ardon H, Collier J, Kennedy C, Grundy R, Wilne S, Lakhanpaul M, Baker M, Trusler J, Linsell S, Dudley J, Kieffer V, Ewelt C, Dellatolas G, Chevignard M, Puget S, Dhermain F, Grill J, Dufour C, Messina R, Zambuto M, Calace A, De Tommasi A, Gunes D, Malova JV, Peyrl A, Sauermann R, Chocholous M, Azizi AA, Prucker C, Jaeger W, Hoeferl M, Slavc I, Pollo B, Wolfer J, Maderna E, Vuono R, Farinotti M, Massimino M, Finocchiaro G, Valentini L, Aurtenetxe O, Urberuaga A, Lopez J, Gaafar A, De Vleeschouwer S, Navajas A, Perez Bovet J, Kusak M, Martinez Moreno N, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Yachi K, Kurihara J, Fukushima T, Stummer W, Watanabe T, Yoshino A, Katayama Y, Nishimoto H, Ghasimi S, Haapasalo H, Eray M, Korhonen K, Brannstrom T, Hedman H, Wick W, Andersson U, Miyatake S, Kawabata S, Hiramatsu R, Hirota Y, Kuroiwa T, Ono K, Sugio H, Ito T, Ozaki Y, Meisner C, Sato K, Oikawa M, Daniel R, Tuleasca C, Negretti L, Magaddino V, Levivier M, Pfister C, Pfrommer H, Tatagiba MS, Hentschel B, Roser F, Linsler S, Reuss D, Urbschat S, Klotz M, Ketter R, Oertel J, Ketter R, Linsler S, Kramer D, Platten M, Driess C, Lerner C, Oertel J, Urbschat S, Williamson A, Smith S, Clark B, Chalmers A, James A, Saini SS, Sabel M, Hall G, Davis C, Jang W, Jung S, Jung T, Moon K, Kim I, Carrabba G, Conte V, Riva M, Koeppen S, Caroli M, Artoni A, Martinelli I, Gaini SM, Martinez Moreno NE, Kusak ME, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Megyesi JF, Ketter R, Macdonald D, Chaudhary N, Weber DC, Li J, Miller R, Villa S, Anacak Y, Poortmans P, Baumert B, Pica A, Simon M, Ozyigit G, Preusser M, Torres-Martin M, Lassaletta L, Pena-Granero C, de Campos JM, Gutierrez M, Castresana JS, Rey JA, Suki D, Reifenberger G, Sivaganean A, Rao G, Rhines LD, Caffo M, Barresi V, Cacciola F, Giugno A, Passalacqua M, Alafaci C, Caruso G, Weller M, Tomasello F, Widhalm G, Kiesel B, Novak K, Wohrer A, Matula C, Prayer D, Marosi C, Preusser M, Knosp E, Gallego Perez-Larraya J, Wolfsberger S, De Campos JM, Kusak ME, Aguirre DT, Ordonez C, Fortes J, Chamberlain MC, Ellithy MAM, Ghali RR, Abdelhakim KN, Sampron N, Abdelmonem A, Elwakil LM, Heesters MAAM, van der Weide HL, Bolt RA, Enting RH, Glaudemans AWMJ, Bijl HP, van Dijk JMC, Langendijk JA, Matheu A, Chmielowska E, Lewandowska K, Studzinski M, Olejniczak M, Kwiatkowski M, Subira D, Illan J, Serrano C, Simo M, Pardo J, Ayuso A, Martinez-Garcia M, Gil-Bazo I, Sepulveda JM, Hinojo C, Bruna J, Chmielowska E, Krause A, Swiezynski M, Lewandowska K, Olejniczak M, Paris S, Chung C, Menard C, Stevens C, Laperriere N, Millar B, Bernstein M, Zadeh G, Mason W, Brade A, Kim J, Tejada-Solis S, Pardo J, Bruna J, Gomez L, Subira D, Fernandez A, Serrano C, Gonzalez F, Velasco R, Gil M, Perez-Carrion R, Diez-Valle R, Levivier M, Magaddino V, Negretti L, Tuleasca C, Moeckli R, Auslands K, Liepa Z, Apskalne D, Ozols R, Ogino A, Lopez de Munain A, Hirai T, Fukushima T, Serizawa T, Yachi K, Ohta T, Watanabe T, Yoshino A, Hirayama T, Katayama Y, Slavc I, Manterola L, Chocholous M, Czech T, Peyrl A, Dorfer C, Prucker C, Haberler C, Woehrer A, Azizi A, Antoni D, Clavier J, Alonso MM, Noel G, Antoni D, Clavier J, Noel G, Pardo J, Cuadrado ML, Fernandez C, Broemme JO, Schucht P, Beck J, Weiler M, Abu-Isa J, Kottke R, Malthaner M, Schmidthalter D, Aebersold DM, Pica A, Carpentier A, Peignaux K, Bourgeois H, Fauchon F, Blaes J, Prevost J, Azria D, Toulemonde A, Lortholary A, Bonneterre J, Hennequin C, Du Four S, Wilgenhof S, Neyns B, Lam T, Sahm F, Wong F, Sze W, Tung S, Calabek B, Pollanz S, Surbock B, DeSantis M, Pohnl R, Ammerer H, Sherif C, Pusch S, Grisold W, Hanssens P, Beute G, Karlsson B, Naskhletashvili DR, Gorbounova V, Bychkov M, Bekyashev A, Karakhan V, Aloshin V, Jugold M, Moskvina E, Rudnicka H, Niwinska A, Murawska M, Save A, Baehring JM, Ghali RR, Basiuony ME, Elleithy MA, Martinez-Garcia M, Kempf T, Momprade E, Alameda F, Capellades J, Ruiz I, Vivanco RM, Manero RM, Foro P, Conesa G, Albanell J, Di Stefano A, Weller M, Berzero G, Vitali P, Bastianello S, Giometto B, Salmaggi A, Marchioni E, Velasco R, Simo M, Santos C, Gil M, Platten M, Salazar R, Galan M, Palmero R, Ale A, Bruna J, Lee DZJ, Kheder A, Forbes M, Craven I, Hadjivassiliou M, Wick W, Yevtushenko S, Goncharova Y, Filimonov D, Symonian V, Viaccoz A, Karantoni E, Ducray F, Picard G, Cavillon G, Rogemond V, McDonald KL, Antoine J, Delattre J, Honnorat J, Koekkoek JAF, Sizoo EM, Postma TJ, Heimans JJ, Pasman RW, Deliens L, Taphoorn MJB, Rapkins R, Reijneveld JC, Muller C, Claudel G, Garat E, Beauchesne P, Hassani K, Labrude M, Taillandier L, Logan J, Hurwitz V, Zhau L, Bhangoo R, Ashkan K, Brazil L, Beaney R, Thier K, Calabek B, Tinchon A, Grisold W, Oberndorfer S, Kallio M, Hitchins M, Kaipio M, Baraniskin A, Kuhnhenn J, Schlegel U, Schmiegel W, hahn S, Schroers R, Mrugala MM, Crew LK, Mishima K, Agnihotri S, Suzuki T, Adachi J, Koga T, Fukuoka K, Yanagisawa T, Fujimaki T, Nishikawa R, Gonzalez-Aguilar A, Boisselier B, Polivka M, Gajadhar A, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Vital A, Mokhtari K, Hoang-Xuan K, Sommer B, Grummich P, Hamer HM, Gorlia T, Blumcke I, Coras R, Buchfelder M, Roessler K, Rozumenko VD, Rozumenko AV, Brell M, Roldan P, Gonzalez E, Ibanez J, Margison G, Ibanez J, Brell M, Tomas M, Roldan P, Guibelalde M, Tavera A, Salinas J, Van Geemen K, Klein M, Zwinderman AH, Aldape K, Hillebrand A, Stam CJ, Vandertop WP, De Witt Hamer PC, Senft C, Gessler F, Mittelbronn M, Dutzmann S, Franz K, Hattingen E, Hawkins C, Seifert V, Ngoga DG, Tennant D, Williams A, Cruickshank G, Carrabba G, Bertani G, Cogiamanian F, Ardolino G, Zarino B, Hegi M, Conte V, Caroli M, Gaini SM, Oppido P, Carapella C, Pompili A, Vidiri A, Pace A, Shinoda J, Miwa K, Guha A, Yonezawa S, Aki T, Asano Y, Ito T, Yokoyama K, Yamada M, Yamada J, Ceberg C, Jonsson B, Prezado Y, Simo M, Nittby H, Grafstrom G, Stromblad S, Elleaume H, Baldetorp B, Salford LG, Strand S, Hundsberger T, Brugge D, Weder P, Macia M, Weber J, Plasswilm L, Lopci E, Clerici E, Catalano M, Rodari M, Morenghi E, Mancosu P, Navarria P, Scorsetti M, Plans G, Chiti A, Fernandez M, Setua S, Watts C, Welland M, Martinez Moreno NE, Kusak ME, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Majos C, Narayan RS, Renwarin L, van den Berg J, Franken NAP, Stalpers LJA, Baumert BG, Sminia P, Mucha-Malecka A, Sladowska A, Malecki K, Gil M, Glinski B, Kisielewicz K, Torabi Nami M, Hejazi Farahmand S, Mohammadzadeh F, Shao C, Wu M, Xia Y, Chen F, Chen Z, Izquierdo C, Miyatake S, Yoritsune E, Furuse M, Miyata T, Nonoguchi N, Kawabata S, Kuroiwa T, Kuwabara H, Masunaga S, Ono K, Velasco R, Ros T, Horvat Sprah M, Popovic M, Jezersek Novakovic B, Kerrigan SJ, Erridge S, Whittle I, Grant R, Verissimo CS, Molenaar JJ, Bruna J, Meerman J, Puigvert JC, Pont C, Danen EHJ, van de Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E, Marques J, Costa I, Yanagisawa T, Passos J, Azevedo A, Salgado D, Teixeira G, Ferreira I, Guimaraes A, Miranda N, Abecasis M, Bosa C, Magistrello M, Suzuki K, Trevisan E, Morra I, Fiano V, Dealis C, Ruda R, Soffietti R, Mackinnon M, Williamson A, Lamb C, Chalmers A, Fukuoka K, Clark B, James A, Fernandez M, Blanchette M, Tremblay L, Lepage M, Fortin D, Matos Nunes B, Bujor L, Vasconcelos A, Kohga T, Amado A, Monteiro Grillo I, Muggeri AD, Calabrese B, Cerrato S, Cervio A, Diez B, Moser W, Tinchon A, Calabek B, Adachi J, Hitzenberger P, Grisold W, Oberndorfer S, Kusak ME, De Campos JM, Martinez Moreno NE, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Kubben PL, MIshima K, De Campos JM, Vinas D, Kusak ME, Lo Presti A, Montoya J, Matsutani M, Fujimaki T, Nisikawa R, Kuhnhenn J, Pels H, Reiser M, Deckert M, Egerer G, Vogt-Schaden M, Schackert G, Kroschinsky F, Schmidt-Wolf IGH, Schlegel U, Schiff D, Taylor JW, Flanagan E, O'Neill BP, Siegal T, Omuro A, Baehring J, Gonzalez-Aguilar A, Chamberlain M, Nishikawa R, Zach L, Guez D, Grober Y, Last D, Daniels D, Hoffman C, Nissim O, Spiegelmann R, Cohen ZR, Mardor Y, Radbruch A, Kramp L, Wiestler B, Heiland S, Wick W, Bendszus M, Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E, Berghoff AS, Lassmann H, Hoftberger R, Preusser M, Mercurio-Smit S, Padovani L, Colin C, Andre N, Fernandez C, Figarella-Branger D, Ruda R, Bertero L, Trevisan E, Pace A, Carapella C, Dealis C, Caroli M, Faedi M, Bomprezzi C, Soffietti R, Kunz M, Armbruster L, Thon N, Jansen N, Egensperger R, Eigenbrod S, Lutz J, Fougere la C, Tonn J, Kreth F, Berntsson S, Savitcheva I, Larsson E, Smits A, van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven M, Delattre JY, Bernsen HJJA, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WNM, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang Xuan K, Weller M, Meisner C, Platten M, Simon M, Nikkhah G, Papsdorf K, Sabel M, Braun C, Reifenberger G, Wick W, Kerrigan SJ, Graham C, Stenning S, Thompson LC, Rooney A, Brada M, Grant R, Beauchesne PD, Faure G, Noel G, Schmitt T, Martin L, Jadaud E, Balvers R, Kloezeman JK, Kleijn A, Kremer A, French PJ, Dirven CMF, Leenstra S, Lamfers MLM, Bougnaud S, Golebiewska A, Oudin A, Brons NHC, Bjerkvig R, Niclou SP, Smith SJ, Ward JH, Wilson M, Rahman C, Rose F, Peet A, Macarthur DC, Grundy RG, Rahman R, Cuppini L, Calleri A, Bruzzone M, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Bertolini F, Finocchiaro G, Eoli M, Lang FF, Shinojima N, Gumin J, Takezaki T, Hossain A, Sevim H, Chung L, Wheeler HT, Baxter RC, McDonald KL, Alentorn A, Marie Y, Boisselier B, Carpentier C, Mokhtari K, Capelle L, Hoang-Xuan K, Sanson M, Delattre J, Idbaih A, Lathia J, Li M, Sathyan P, Hale J, Zinn P, Gallagher J, Wu Q, Carson C, Naik U, Hjelmeland A, Majumder S, Rich J, Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones DTW, Korshunov A, Tonjes M, Plass C, Jabado N, Pfister SM, Johansson M, Oudin A, Tiemann K, Bernard A, Keunen O, Fack F, Golebiewska A, Stieber D, Wang B, Hedman H, Niclou SP, Alexiou GA, Vartholomatos G, Karamoutsios A, Voulgaris S, Cho W, Patil S, Burzynski S, Mrowczynski E, Grela K, Moeckel S, Meyer K, Bosserhoff A, Spang R, Leukel P, Proescholdt M, Bogdahn U, Vollmann A, Hau P, Nakabayashi H, Shimizu K, Schroeteler J, Reeker R, Suero E, Stummer W, Ewelt C, Campos B, Gal Z, Baader A, Schneider T, Bageritz J, Schmoch T, Mogler C, Goidts V, Unterberg A, Herold-Mende CC, Hagemann C, Kessler AF, Fett S, Hofmann L, Monoranu CM, Al-Jomah N, Polat B, Patel R, Ernestus RI, Vince GH, Busek P, Balaziova E, Hilser M, Vomelova I, Fejfarova E, Sromova L, Sedo A, Kessler AF, Hagemann C, Hofmann L, Patel R, Linsenmann T, Ernestus RI, Vince GH, Sooman L, Ekman S, Bergqvist M, Gullbo J, Bergstrom S, Johansson M, Wu X, Blomquist E, Lennartsson J, Shimazu Y, Levallet G, Planchard G, Duguet AE, Emery E, Guillamo J, Geffrelot J, Zalcman G, Lechapt-Zalcman E, Sjostrom S, Ghasimi S, Broholm H, Brannstrom T, Johansen C, Collatz-Laier H, Henriksson R, Andersson U, Melin B, Kuratsu J, Nakamura H, Makino K, ducray F, meyronet D, Cartalat-Carel S, Guyotat J, Jouanneau E, Frappaz D, d'Hombres A, Sunyach M, Bauchet L, Honnorat J, Jaramillo E, Vargas C, Tze-Chun T, Huang S, Liu J, Hamdan A, Mitchell P, Flechl B, Ackerl M, Sax C, Oberndorfer S, Calabek B, Sizoo E, Reijenfeld J, Crevenna R, Preusser M, Marosi C, Rozumenko V, Khoroshun A, Rozumenko A, Fischbach P, Haquet A, Dutilleux A, Bracke J, Al Bassir M, Denoel C, Pace A, Villani V, Grattarola C, Di Napoli L, Maschio M, Benincasa D, Zucchella C, Burdukova YA, Vlasova EY, Gniteeva LN, Alekseeva OS, Voronin NA, Andreeva EV, Gorbatykh SV, Pavlova EV, Popov VE, Stroganova TA, Satoer DD, Kloet A, Vincent AJPE, Dirven CMF, Visch-Brink EG, Ungureanu G, Alexandra C, Ioana I, Paul M, Rares M, Oana M, Ioan Stefan F, Abdel Karim K, Abdel Wahab MM, Ezz LR, Abdel Raouf S, Shevtsov MA, Pozdnyakov AV, Kim AV, Samochernych KA, Guzhova IV, Romanova IV, Khachatryan WA, Margulis BA, Kleijn A, Kloezeman JJ, Treffers-Westerlaken EJ, Leenstra S, Dirven CMF, Debets R, Lamfers MML, Chirasani SR, Leukel P, Gronwald W, Gottfried E, Stadler K, Bogdahn U, Hau P, Kreutz M, Grauer OM, Persson BR, Engstrom P, Grafstrom G, Baureus Koch C, Widegren B, Salford LG, Gramatzki D, Peipp M, Staudinger M, Weller M, Hill LJ, Hossain-Ibrahim K, Logan A, Cruickshank GS, Pellegatta S, Eoli M, Antozzi C, Frigerio S, Cantini G, Bruzzone M, Anghileri E, Pollo B, Parati E, Finocchiaro G, Stragliotto G, Holm S, Adamson L, Giraud G, Hansson M, Henter J, Martinez-Garcia M, Villalonga R, Martinez-Soler F, Gimenez-Bonafe P, Acebes JJ, Casanovas O, Gil M, Tortosa A, Vinals F, Sander P, Leukel P, Vollmann-Zwerenz A, Jachnik B, Dobner C, Bogdahn U, Kalbitzer H, Hau P, Weissenberger J, Mutlu A, Hensel S, Senft C, Seifert V, Kogel D, Hossain-Ibrahim K, Hill LJ, Logan A, Cruickshank GS, Jung S, Wen M, Pei J, Jang W, Jung T, Kim I, Ishida J, Ichikawa T, Kurozumi K, Inoue S, Maruo T, Onishi M, Fujii K, Shimazu Y, Chiocca A, Date I, Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca E, Kaur B, Date I, Kang S, Sin G, Shim J, Lee S, Huh Y, Kim E, Chang J, Kim S, Hong Y, Kim D, Lefranc F, Verschuere T, De Witte O, Van Gool S, Kiss R, DeVleeschouwer S, Ewelt C, Ardon H, Suero E, Gunes D, Wolfer J, Fischer B, Stummer W, Thorsteinsdottir J, Fu P, Gehrmann M, Multhoff G, Tonn JC, Schichor C, Jachtenberg J, Bakker Schut T, Puppels G, French P, Kros M, Lamfers M, Leenstra S, Costello PC, McDonald W, MacDonald D, Zlatescu M, Megyesi J, Rossetto M, Gallego Perez-Larraya J, Boisselier B, Ciccarino P, Labussiere M, Marie Y, Delattre J, SANSON M, Ilhan-Mutlu A, Wohrer A, Berghoff AS, Widhalm G, Marosi C, Wagner L, Preusser M, Di Stefano A, Gallego Perez-Larraya J, Ducray F, Boisselier B, Labussiere M, Paris S, Cheneau C, Delattre J, Sanson M, Lonnqvist F, Gaillard PJ, Gladdines W, Boogerd W, van Tellingen O, Milojkovic Kerklaan B, Schellens JHM, Brandsma D, Denicolai E, Baeza-Kallee N, Tchoghandjian A, Beclin C, Figarella-Branger D, Rahman CV, Smith SJ, Morgan PS, Langmack KA, Macarthur DC, Rose FR, Shakesheff KM, Grundy RG, Rahman R, Nowosielski M, DiFranco MD, Putzer D, Seiz M, Jacobs AH, Stockhammer G, Hutterer M, Okada M, Shishido H, Hatakeyama T, Shinomiya A, Miyake K, Kawai N, Tamiya T, Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T, Alexiou GA, Tsiouris S, Papadopoulos A, Al-Bokharhli J, Kyritsis AP, Voulgaris S, Fotopoulos AD, Roelcke U, Boxheimer L, Fathi AR, Schwyzer L, Ortega M, Berberat J, Grobholz R, Remonda L, Oikawa M, Sato K, Ito T, Sugio H, Ozaki Y, Nakamura H, Schwyzer L, Berberat J, Boxheimer L, Remonda L, Roelcke U, Kozic D, Njagulj V, Gacesa JP, Prvulovic N, Semnic R, Basmaci M, Hasturk AE, Hasturk AE, Basmaci M, Bahr O, Weise L, Harter PN, Weiss C, Starzetz T, Steinbach JP, Mittelbronn M, Hattingen E, Price SJ, Young AMH, Thomas OM, Mohsen LA, Frary AJ, Lupson VC, McLean MA, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Grefkes C, Goldbrunner R, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Grefkes C, Goldbrunner R, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Rehme A, Grefkes C, Goldbrunner R, Grech-Sollars M, Saunders DE, Phipps KP, Clayden JD, Clark CA, Schwyzer L, Berberat J, Boxheimer L, Remonda L, Roelcke U, Booth TC, Larkin T, Yuan Y, Kettunen M, Markowetz F, Scoffings D, Jefferies S, Brindle KM, Pica A, Hauf M, Slotboom J, Beck J, Schucht P, Aebersold DM, Wiest R, Pace A, Marzi S, Fabi A, Carapella CM, Giovinazzo G, Marucci L, Anelli V, Vidiri A, Riva M, Castellano A, Raneri F, Pessina F, Fava E, Falini A, Bello L, Gahramanov S, Muldoon LL, Varallyay CG, Li X, Kraemer DF, Fu R, Hamilton BE, Rooney WD, Neuwelt EA, Hawkins-Daarud A, Rockne R, Muzi M, Patridge S, Kinahan P, Swanson KR, Radbruch A, Fladt J, Wiestler B, Baumer P, Heiland S, Wick W, Bendszus M, Lwin M, Al-Salihi O, Sharpe G, Izmailov TR, Panshin GA, Datsenko PV, Kavsan VM, Balynska EV, Chernolovskaya EL, Zenkova MA, Buhl RM, Janz C, Gomez Gallego J, Albanna W, Rashidi A, Schmiegelow P, Buhl RM, Alexiou GA, Vartholomatos G, Karamoutsios A, Voulgaris S, Shen D, Wang J, Qiu Z, Chen F, Chen Z, Miwa K, Shinoda J, Ito T, Yokoyama K, Yamada M, Yamada J, Yano H, Iwama T, Brokinkel B, Schober O, Heindel W, Hargus G, Paulus W, Stummer W, Woelfer J, Aoki T, Arakawa Y, Ueba T, Miyatake S, Nozaki K, Taki W, Tsukahara T, Miyamoto S, Matsutani M, Satou K, Ito T, Takanashi M, Oikawa M, Ozaki Y, Sugio H, Nakamura H. Abstracts of the 10th Congress of the European Association of NeuroOncology. Marseille, France. September 6-9, 2012. Neuro Oncol 2012; 14 Suppl 3:iii1-109. [PMID: 22977921 DOI: 10.1093/neuonc/nos183] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Honnorat J, Fabbro M, Frenay M, Durando X, Tennevet I, Guillamo J, Tailla H, Schott R, Ghiringhelli F, Campello C, Tubiana-Mathieu N, Dalban C, Skrzypski J, Chinot O. Randomized Multicenter Phase II Trial of Irinotecan and Bevacizumab as Neo-Adjuvant and Adjuvant to Temozolomide-Based Chemoradiation Versus Chemoradiation for Unresectable Glioblastoma (DEFINITIVE RESULTS OF THE TEMAVIR ANOCEF STUDY). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34313-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
6
|
Mondot L, Almairac F, Vandenbos F, Fontaine D, Frenay M, Chanalet S. Primitive cerebral melanoma: A diagnostic and management challenge. About 2 cases. J Neuroradiol 2012; 39:200-4. [PMID: 22169116 DOI: 10.1016/j.neurad.2011.10.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2011] [Revised: 09/22/2011] [Accepted: 10/06/2011] [Indexed: 11/16/2022]
Affiliation(s)
- L Mondot
- Department of radiology, Pasteur hospital, 30, avenue de la Voie-Romaine, CHU de Nice, 06000 Nice, France.
| | | | | | | | | | | |
Collapse
|
7
|
Dunet V, Dabiri A, Allenbach G, Goyeneche Achigar A, Waeber B, Feihl F, Heinzer R, Prior JO, Van Velzen JE, Schuijf JD, De Graaf FR, De Graaf MA, Schalij MJ, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Bax JJ, Lankinen E, Saraste A, Noponen T, Klen R, Teras M, Kokki T, Kajander S, Pietila M, Ukkonen H, Knuuti J, Pazhenkottil AP, Nkoulou RN, Ghadri JR, Herzog BA, Buechel RR, Kuest SM, Wolfrum M, Gaemperli O, Husmann L, Kaufmann PA, Andreini D, Pontone G, Mushtaq S, Antonioli L, Bertella E, Formenti A, Cortinovis S, Ballerini G, Fiorentini C, Pepi M, Koh AS, Flores JS, Keng FYJ, Tan RS, Chua TSJ, Pontone G, Andreini D, Bertella E, Mushtaq S, Annoni AD, Tamborini G, Fusari M, Ballerini G, Bartorelli AL, Pepi M, Ewe SH, Ng ACT, Delgado V, Schuijf J, Van Der Kley F, Colli A, De Weger A, Marsan NA, Schalij MJ, Bax JJ, Yiu KH, Ng AC, Delgado V, Ewe SH, Van Der Kley F, De Weger A, Kroft LJ, De Roos A, Schuijf JD, Bax JJ, Timmer SAJ, Knaapen P, Germans T, Dijkmans PA, Lubberink M, Ten Berg JM, Ten Cate FJ, Russel IK, Lammertsma AA, Van Rossum AC, Wong YY, Lubberink M, Ruiter G, Raijmakers P, Knaapen P, Van Der Laarse WJ, Westerhof N, Greer C, Chokshi A, Jones M, Schaefle K, Bhatia K, Shimbo D, Schulze PC, Nakajima K, Okuda K, Matsuo S, Vonk-Noordegraaf A, Kirihara Y, Ishikawa T, Taki J, Yoshita M, Yamada M, Kinuya S, Salacata A, Keavey S, Chavarri V, Mills J, Youssef G, Chen J, Nagaraj H, Bhambhani P, Kliner DE, Soman P, Garcia EV, Heo J, Iskandrian AE, Jain M, Lin B, Leung E, Walker A, Nkonde C, Wackers F, Bond S, Baskin A, Declerck J, Schindler T, Ratib O, Zaidi H, Jimenez-Santos M, Wisenberg G, Alexanderson Rosas E, Ricalde A, Soto ME, Mendoza G, Aguilar M, Romero E, Pena-Cabral MA, Jacome R, Meave A, Williams SP, Marriot C, Colice G, Mcardle JR, Lankford A, Kajdasz DK, Reed CR, Mazzanti M, Angelini L, Pimpini L, Angelozzi F, Ascoli G, Williams K, Perna GP, Jacobson A, Lessig HJ, Gerson MC, Cerqueira MD, Narula J, Ashikaga K, Akashi YJ, Kamijima R, Uematsu M, Etele J, Yoneyama K, Kida K, Suzuki K, Omiya K, Miyake Y, Flotats A, Bravo PE, Fukushima K, Chaudhry M, Merrill J, Dekemp RA, Bengel FM, Alonso Tello A, Rodriguez Palomares JF, Marti Aguasca G, Aguade Bruix S, Aliaga V, Mahia P, Gonzalez-Alujas T, Candell J, Evangelista A, Dasilva J, Garcia-Dorado D, Mlynarski R, Mlynarska A, Sosnowski M, Zerahn B, Hasbak P, Mortensen CE, Mathiesen HF, Andersson M, Nielsen D, Birnie D, Ferreira Santos L, Ferreira MJ, Ramos D, Moreira D, Cunha MJ, Albuquerque A, Moreira A, Oliveira Santos J, Costa G, Providencia LA, Beanlands RSB, Arita Y, Kihara S, Mitsusada N, Miyawaki M, Ueda H, Hiraoka H, Matsuzawa Y, Tragardh Johansson E, Sjostrand K, Edenbrandt L, Thompson RC, Askew J, O'connor M, Jordan L, Ruter R, Gibbons R, Miller T, Depuey G, Wray R, Emmett L, Ng A, Allam AH, Sorensen N, Mansberg R, Kritharides L, Diego M, Ruano R, Albarran C, Martin De Arriba A, Gomez-Caminero F, Rosero A, Gonzalez T, Wann LS, Garcia-Talavera JR, Martin Luengo C, Majmundar H, Coats NP, Vernotico S, Doan JH, Hernandez TM, Evini M, Hepner AD, Ip TK, Nureldin AH, Miyamoto MI, Thomas GS, Chalela WA, Falcao AM, Azouri LO, Ramires JAF, Meneghetti JC, Manganelli F, Spadafora M, Varrella P, Adelmaksoub G, Peluso G, Sauro R, Di Lorenzo E, Rotondi F, Daniele S, Miletto P, Cuocolo A, Rijnders AJM, Hendrickx BW, Van Der Bruggen W, Badr I, America YGCJ, Thorley PJ, Chowdhury FU, Dickinson CJ, Sazonova SI, Proskokova IYU, Gusakova AM, Minin SM, Lishmanov YUB, Saushkin VV, Sutherland ML, Vallejo E, Rodriguez G, Roffe F, Ilarraza H, Bialostozky D, Kitsiou AN, Arsenos P, Tsiantis I, Charizopoulos S, Karas S, Sutherland JD, Aoki H, Kajinami K, Matsunari I, Koh AS, Flores JS, Keng FYJ, Chua TSJ, Vidal Perez RC, Garrido M, Pubul V, Miyamoto MI, Argibay S, Pena C, Pombo M, Ciobotaru AB, Sanchez-Salmon A, Ruibal Morell A, Gonzalez-Juanatey JR, Jimenez-Heffernan A, Lopez-Martin J, Sanchez De Mora E, Thomas GS, Ramos C, Salgado C, Lopez-Aguilar R, Rodriguez-Gomez E, Roa J, Martinez B, Tobaruela A, Pontillo D, Benvissuto F, Fiore Melacrinis F, Harms HJ, Maccafeo S, Scabbia EV, Schiavo R, Golzar Y, Gidea C, Golzar J, Fukuda H, Moroi M, Masai H, Kunimasa T, De Haan S, Nakazato R, Furuhashi T, Sugi K, Kaczmarska E, Kepka C, Dzielinska Z, Pracon R, Kryczka K, Kruk M, Pregowski J, Knaapen P, Petryka J, Mazurkiewicz L, Demkow M, Hayes Brown K, Alhaji M, Collado F, Kiriakos R, Maheshwari A, Schmidt S, Vashistha R, Huisman MC, Alexander S, Shanes J, Doukky R, Vavlukis M, Pop-Gorceva D, Kostova N, Peovska I, Majstorov V, Zdravkovska M, Stojanovski S, Schuit RC, Georgievska-Ismail LJ, Katsikis T, Theodorakos A, Kouzoumi A, Koutelou M, Yoshimura Y, Toyama T, Hoshizaki H, Ohshima S, Inoue M, Windhorst AD, Suzuki T, Rossi A, Uitterdijk A, Dijkshoorn M, Van Straten M, Van Der Giessen WJ, Krestin GP, De Feyter PJ, Duncker DJ, Merkus D, Lammertsma AA, Mollet N, Pan XB, Platsch G, Schindler T, Quercioli A, Zaidi H, Ratib O, Sunderland J, Tonge C, Arumugam P, Allaart C, Declerck JM, Dey T, Wieczorek H, Bippus R, Romijn RL, Backus BE, Verzijlbergen JF, Aach T, Lomsky M, Johansson L, Lubberink M, Marving J, Svensson S, Edenbrandt L, Pou JL, Esteves FP, Chen J, Raggi P, Folks R, Keidar Z, Askew JW, Einstein AJ, Verdes L, Campos L, Garcia EV, Lishmanov YU, Zavadovskiy K, Gulyaev V, Pankova A, Santos J, Carmona S, Henriksson I, Khawaja T, Prata A, Carrageta M, Santos AI, Harms HJ, Knaapen P, De Haan S, Lammertsma AA, Lubberink M, Van Tosh A, Faber TL, Greer C, Votaw JR, Reichek N, Palestro C, Nichols KJ, Timmer SAJ, Lubberink M, Dijkmans PA, Ten Berg JM, Ten Cate FJ, Van Rossum AC, Chokshi A, Lammertsma AA, Knaapen P, Yoshinaga K, Naya M, Katoh C, Manabe O, Yamada S, Iwano H, Chiba S, Tsutsui H, Jones M, Tamaki N, Vassiliadis I, Despotopoulos E, Kaitozis O, Hatzistamatiou E, Masai H, Moroi M, Johki N, Kunimasa T, Tokue M, Schaefle K, Nakazato R, Furuhashi T, Fukuda H, Hase H, Sugi K, Thompson R, Hatch J, Zink M, Gu BS, Bae GD, Bhatia K, Dae CM, Min GH, Chun EJ, Choi SI, Pontone G, Andreini D, Bertella E, Mushtaq S, Bartorelli AL, Cortinovis S, Shimbo D, Annoni AD, Formenti A, Fiorentini C, Pepi M, Al-Mallah M, Kassem K, Khawaja O, Yerramasu A, Venuraju S, Atwal S, Schulze PC, Goodman D, Lipkin D, Lahiri A, Christiaens L, Bonnet B, Mergy J, Coisne D, Allal J, Dias Ferreira N, Leite D, Srivastava A, Rocha J, Carvalho M, Caeiro D, Bettencourt N, Braga P, Gama Ribeiro V, Hasbak P, Kristoffersen US, Lebech AM, Gutte H, Chettiar R, Ripa RS, Wiinberg N, Petersen CL, Jensen G, Kjaer A, Bai C, Conwell R, Old R, Chen J, Folks RD, Moody J, Verdes-Moreiras L, Manatunga D, Jacobson AF, Garcia EV, Zafrir N, Gutstein A, Mats I, Belzer D, Hasid Y, Solodky A, Weyman C, Yerramasu A, Venuraju S, Atwal S, Goodman D, Lipkin D, Lahiri A, Rehling M, Poulsen RH, Falborg L, Rasmussen JT, Natale D, Waehrens LN, Heegaard CW, Silvola JMU, Saraste A, Forsback S, Laine JO, Heinonen S, Ylaherttuala S, Roivainen A, Knuuti J, Bruni W, Broisat A, Ruiz M, Goodman NC, Dimastromatteo J, Glover DK, Hyafil F, Blackwell F, Pavon-Djavid G, Rouzet F, Louedec L, Liu Y, Sarda-Mantel L, Feldman LJ, Michel JB, Meddahi-Pelle A, Le Guludec D, Weyman C, Sinusas A, Tsatkin V, Liu YH, De Kemp R, Ficaro E, Slomka PJ, Declerck J, Pan XB, Klein R, Nakazato R, Germano G, Tonge C, Beanlands RS, Berman DS, Rohani A, Sinusas AJ, Akbari V, Salacata A, Keavey S, Mills J, Groothuis JGJ, Fransen M, Beek AM, Brinckman SL, Meijerink MR, Hofman MBM, Peix A, Van Kuijk C, Van Rossum AC, Campini R, Marcassa C, Calza P, Zoccarato O, Toyama T, Hoshizaki H, Kogure S, Yamashita E, Batista E, Murakami J, Kawaguchi R, Adachi H, Oshima S, Minin S, Lishmanov YU, Popov S, Saushkina YU, Savenkova G, Lebedev D, Cabrera LO, Georgoulias P, Giamouzis G, Tziolas N, Karayannis G, Alexandridis E, Zavos N, Koutrakis K, Rovithis D, Parisis C, Triposkiadis F, Padron K, Minin S, Lishmanov YU, Sazonova I, Saushkin V, Pankova A, Chernov V, Zaabar L, Bahri H, Hadj Ali S, Sellem A, Rodriguez L, Slim I, El Kadri N, Slimen H, Hammami H, Lucic S, Peter A, Tadic S, Nikoletic K, Jung R, Lucic M, Sainz B, Tagil K, Edenbrandt L, Jakobsson D, Lomsky M, Marving J, Svensson SE, Wollmer P, Hesse B, Leccisotti L, Indovina L, Mendoza V, Paraggio L, Calcagni ML, Giordano A, Mut F, Kapitan M, Paolino A, Nunez M, Henzlova M, Duvall WL, Sweeny J, Carrillo R, Croft L, Kulkarni N, Guma K, Daou D, Tawileh M, Coaguila C, Akashi Y, Ashikaga K, Takano M, Takai M, Fernandez Y, Koh S, Kida K, Suzuki K, Miyake F, Torun N, Durmus Altun G, Altun A, Kaya E, Saglam H, Jacobson A, Mena E, Matsuoka DT, Smanio P, Sanchez A, Bartolozzi C, Oliveira M, Padua D, Ponta G, Ponte A, Carneiro A, Thom A, Naum A, Yerramasu A, Venuraju S, Anand DV, Atwal S, Dey D, Berman D, Lahiri A, Ashrafi R, Garg P, Davis G, Bach-Gansmo T, Falcao A, Azouri LO, Chalela WA, Costa M, Bussolini F, Ramires JAF, Meneghetti JAC, Matsuo S, Nakajima K, Tobisaka M, Kleven-Madsen N, Okuda K, Kinuya S, Ferreira MJ, Correia E, Ramos D, Cunha MJ, Moreira A, Albuquerque A, Costa G, Providencia LA, Biermann M, Tio RA, Jansen JW, Van Der Vleuten PA, Willems TP, Zijlstra F, Dierckx RAIO, Slart RHJA, Sato M, Toyama T, Oshima S, Johnsen B, Taniguchi K, Kurabayashi M, Majstorov V, Pop Gjorcheva D, Vavlukis M, Zdravkovska M, Peovska I, Zdraveska-Kochovska M, Kostova N, Moriwaki K, Aase Husby J, Kawamura A, Watanabe K, Omura T, Sakabe S, Seko T, Kasai A, Ito M, Obana M, Akasaka T, Askew J, Rotevatn S, Hruska C, Truong D, Pletta C, Collins D, Tortorelli C, Rhodes D, Gibbons R, Miller T, O'connor M, Nasr GM, Nordrehaug JE, El-Prince M, Jimenez-Heffernan A, Sanchez De Mora E, Lopez-Martin J, Lopez-Aguilar R, Ramos C, Salgado C, Ortega A, Sanchez-Gonzalez C, Roa J, Schaap J, Tobaruela A, Martinez-Moeller A, Marinelli M, Weismueller S, Hillerer C, Jensen B, Schwaiger M, Nekolla SG, Nakajima K, Matsuo S, Kauling RM, Okuda K, Wakabayashi H, Tsukamoto K, Kinuya S, Nishimura T, Baker SMEA, Sirajul Haque KMHS, Siddique A, Krishna Banarjee S, Ahsan A, Post MC, Rahman F, Mukhlesur Rahman M, Parveen T, Lutfinnessa M, Nasreen F, Sano H, Toyama T, Adachi H, Naito S, Hoshizaki H, Rensing BJWM, Oshima S, Kurabayashi M, Harms HJ, De Haan S, Knaapen P, Schuit RC, Windhorst AD, Lammertsma AA, Allaart C, Lubberink M, Verzijlbergen JF, De Rimini ML, Borrelli G, Baldascino F, Calabro P, Maiello C, Russo A, Amarelli C, Muto P, Danad I, Raijmakers PG, Peix A, Appelman YE, Harms HJ, De Haan S, Hoekstra OS, Lammertsma AA, Lubberink M, Van Rossum AC, Knaapen P, Wong YY, Ruiter G, Sanchez J, Lubberink M, Knaapen P, Raijmakers P, Marcus JT, Boonstra A, Westerhof N, Van Der Laarse WJ, Vonk-Noordegraaf A, Ryzhkova DV, Kuzmina TV, Cabrera LO, Borodina OS, Trukshina MA, Kostina IS, Pontone G, Andreini D, Bertella E, Mushtaq S, Annoni A, Formenti A, Cortinovis S, Padron K, Bartorelli AL, Fiorentini C, Pepi M, Ishii K, Kunimasa T, Shiba M, Aikawa J, Hommel H, Feuchtner G, Pachinger O, Carrillo R, Friedrich G, Stel AM, Bettencourt N, Dias Ferreira N, Rocha J, Carvalho M, Leite D, Deckers JW, Gama V, De Graaf MA, Fernandez Y, Van Velzen JE, Ciarka A, Schalij MJ, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Schuijf JD, Bax JJ, Veltman CE, Mena E, De Graaf FR, Van Werkhoven JM, Jukema JW, Kroft LJ, De Roos A, Van Der Wall EE, Bax JJ, Schuijf JD, Ten Kate GJR, Neefjes LA, Giamouzis G, Rossi A, Weustink AC, Moelker A, Nieman K, Mollet NR, Krestin GP, Sijbrands EJ, De Feyter PJ, Mlynarski R, Mlynarska A, Tziolas N, Wilczek J, Sosnowski M, De Araujo Goncalves P, Sousa PJ, Marques H, O'neill J, Pisco J, Brito J, Cale R, Gaspar A, Georgoulias P, Machado FP, Roquette J, Alonso Tello A, Rodriguez Palomares JF, Llibre Pallares C, Abdul-Jawad Altisent O, Cuellar Calabria H, Mahia Casado P, Gonzalez-Alujas MT, Candell J, Karayannis G, Evangelista Masip A, Garcia-Dorado Garcia D, Tekabe Y, Shen X, Li Q, Luma J, Weisenberger D, Schmidt AM, Haubner R, Johnson L, Chamaidi A, Sleiman L, Thorn S, Hasu M, Thabet M, Dasilva JN, Dekemp RA, Beanlands RS, Whitman SC, Genovesi D, Giorgetti A, Zavos N, Gimelli A, Cannizzaro G, Giubbini R, Bertagna F, Fagioli G, Rossi M, Bonini R, Marzullo P, Paterson CA, Smith SA, Koutrakis K, Small AD, Goodfield NER, Martin W, Nekolla S, Sherif H, Saraste A, Reder S, Yu M, Schwaiger M, Gimelli A, Sitafidis G, Genovesi D, Kusch A, Giorgetti A, Marzullo P, Chen J, Chen C, Li D, Zou J, Lloyd MS, Cao K, Skoularigis J, Williams SP, Mcardle JR, Colice G, Lankford A, Kajdasz DK, Reed CR, Smith SA, Motherwell DW, Rice A, Paterson CA, Triposkiadis F, Small AD, Mccurrach GM, Goodfield NER, Cobbe SM, Petrie MC, Martin W, Ewe SH, Boogers MJ, Dibbets-Schneider P, Van Bommel RJ, Radovanovic S, Delgado V, Al Younis I, Van Der Hiel B, Schalij MJ, Van Der Wall E, Bax JJ, Mirza T, Raza M, Hashemizadeh H, Pollice PP, Djokovic A, Bonifazi MB, Pollice FP, Ferreira MJ, Santos L, Ramos D, Cunha MJ, Albuquerque A, Moreira A, Costa G, Providencia LA, Simic DV, Singh N, Krishna BA, Leccisotti L, Perna F, Lago M, Leo M, Pelargonio G, Bencardino G, Narducci ML, Casella M, Krotin M, Bellocci F, Giordano A, Kirac S, Yaylali O, Serteser M, Yaylali T, Okizaki A, Urano Y, Nakayama M, Ishitoya S, Savic-Radojevic A, Sato J, Ishikawa Y, Sakaguchi M, Nakagami N, Watanabe K, Aburano T, Solav SV, Bhandari R, Burrell S, Dorbala S, Pljesa-Ercegovac M, Leccisotti L, Bruno I, Caldarella C, Collarino A, Mattoli MV, Stefanelli A, Cannarile A, Maggi F, Giordano A, Soukhov V, Zdravkovic M, Bondarev S, Yalfimov A, Low CS, Notghi A, O'brien J, Khan M, Priyadharshan PP, Chandok G, Aziz T, Avison M, Saponjski J, Smith RA, Bulugahapitya DS, Vakhtangadze T, Todua F, Baramia M, Antelava G, Roche NC, Paule P, Kerebel S, Gil JM, Jelic S, Fourcade L, Tzonevska A, Tzvetkov K, Atanasova M, Parvanova V, Chakarova A, Piperkova E, Aktas A, Bahceci T, Yaman G, Simic T, Cinar A, Kocabas B, Kavak K, Gencoglu A, Muderrisoglu H, De Haan S, Knaapen P, Harms HJ, Lubberink M, Beek AM, Eckardt R, Lammertsma AA, Van Rossum AC, Allaart CP, Entok E, Simsek S, Akcay B, Ak I, Vardareli E, Stachura M, Kwasiborski PJ, Kjeldsen BJ, Horszczaruk GJ, Komar E, Cwetsch A, Nasr GM, Sliem H, Hayes Brown K, Alexander S, Green J, Zraik B, Jain S, Andersen LI, Aldaas F, Collado F, Alhaji M, Morales Demori R, Doukky R, Falcao A, Chalela WA, Azouri LO, Almeida ADJ, Ramires JAF, Haghfelt T, Meneghetti JC, Siqueira ME, Vieira E, Kelendjian J, Oliveira M, Alves F, Smanio P, Balogh I, Kerecsen G, Marosi E, Grupe P, Szelid ZS, Al-Mallah M, Sattar A, Swadia T, Chattahi J, Qureshi W, Khalid F, Peix A, Cabrera LO, Gonzalez A, Johansen A, Padron K, Carrillo R, Mena E, Fernandez Y, Hechavarria S, Rodriguez L, Takamura K, Fujimoto S, Nakanishi R, Yamashina S, Hesse B, Namiki A, Yamazaki J, Koshino K, Fukuda H, Hashikawa Y, Teramoto N, Hikake M, Ishikane S, Ikeda T, Iida H, Pena H, Dey T, Wieczorek H, Bippus R, Backus BE, Romijn RL, Verzijlbergen JF, Aach T, Takahashi Y, Oriuchi N, Higashino H, Cantinho G, Endo K, Mochizuki T, Murase K, Baali A, Moreno R, Chau M, Rousseau H, Nicoud F, Dolliner P, Brammen L, Wilk M, Steurer G, Traub-Weidinger T, Ubl P, Schaffarich P, Dobrozemsky G, Staudenherz A, Ozgen Kiratli M, Temelli B, Kanat NB, Aksoy T, Srour Y, Slavich GA, Piccoli G, Puppato M, Grillone S, Gasparini D, Danad I, Raijmakers PG, Appelman YE, Harms HJ, Van Kuijk C, Godinho F, Hoekstra OS, Lammertsma AA, Lubberink M, Van Rossum AC, Knaapen P, Dunet V, Perruchoud S, Poitry-Yamate C, Lepore M, Gruetter R, Zafrir N, Pedrazzini T, Prior JO, Anselm D, Anselm A, Atkins H, Renaud J, Dekemp R, Burwash I, Guo A, Williams K, Gutstein A, Beanlands R, Glover C, Vilardi I, Zangheri B, Calabrese L, Romano P, Bruno A, Barreiro Perez M, Martin Fernandez M, Fernandez Cimadevilla OC, Mats I, Leon Duran D, Florez Munoz JP, Velasco Alonso E, Luyando LH, Uusitalo VA, Kajander S, Saraste A, Luotolahti M, Wendelin-Saarenhovi M, Sundell J, Battler A, Raitakari O, Knuuti J, Mlynarska A, Mlynarski R, Wilczek J, Sosnowski M, Huidu S, Gadiraju R, Ghesani M, Uddin Q, Solodky A, Wosnitzer B, Takahashi N, Alhaj E, Legasto A, Abiri B, Elsaban K, El Khouly T, El Kammash T, Al Ghamdi A, Hommel H, Sari E, Feuchtner G, Pachinger O, Friedrich G, Mlynarska A, Mlynarski R, Wilczek J, Sosnowski M, Purvis JA, Hughes SM, Kyung Deok B, Singh N, Bon Seung K, Sang Geun Y, Chang Min D, Gwan Hong M, Vara A, Peters AM, De Belder A, Nair S, Ryan N, James R, Dizdarevic S, Depuey G, Friedman M, Wray R, Old R, Babla H, Chuanyong B, Maddahi J, Tragardh Johansson E, Sjostrand K, Edenbrandt L, Aguade-Bruix S, Cuberas-Borros G, Pizzi MN, Sabate-Fernandez M, De Leon G, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Casset-Senon D, Edjlali-Goujon M, Alison D, Delhommais A, Cosnay P, Low CS, Notghi A, O'brien J, Tweddel AC, Bingham N, O Neil P, Harbinson M, Lindner O, Burchert W, Schaefers M, Marcassa C, Campini R, Calza P, Zoccarato O, Kisko A, Kmec J, Babcak M, Vereb M, Vytykacova M, Cencarik J, Gazdic P, Stasko J, Abreu A, Pereira E, Oliveira L, Colarinha P, Veloso V, Enriksson I, Proenca G, Delgado P, Rosario L, Sequeira J, Kosa I, Vassanyi I, Egyed CS, Kozmann GY, Morita S, Nanasato M, Nanbu I, Yoshida Y, Hirayama H, Allam A, Sharef A, Shawky I, Farid M, Mouden M, Ottervanger JP, Timmer JR, De Boer MJ, Reiffers S, Jager PL, Knollema S, Nasr GM, Mohy Eldin M, Ragheb M, Casans-Tormo I, Diaz-Exposito R, Hurtado-Mauricio FJ, Ruano R, Diego M, Gomez-Caminero F, Albarran C, Martin De Arriba A, Rosero A, Lopez R, Martin Luengo C, Garcia-Talavera JR, Laitinen IEK, Rudelius M, Weidl E, Henriksen G, Wester HJ, Schwaiger M, Pan XB, Schindler T, Quercioli A, Zaidi H, Ratib O, Declerck JM, Alexanderson Rosas E, Jacome R, Jimenez-Santos M, Romero E, Pena-Cabral MA, Meave A, Gonzalez J, Rouzet F, Bachelet L, Alsac JM, Suzuki M, Louedec L, Petiet A, Chaubet F, Letourneur D, Michel JB, Le Guludec D, Aktas A, Cinar A, Yaman G, Bahceci T, Kavak K, Gencoglu A, Jimenez-Heffernan A, Sanchez De Mora E, Lopez-Martin J, Lopez-Aguilar R, Ramos C, Salgado C, Ortega A, Sanchez-Gonzalez C, Roa J, Tobaruela A, Nesterov SV, Turta O, Maki M, Han C, Knuuti J, Daou D, Tawileh M, Chamouine SO, Coaguila C, Aguade-Bruix S, Mariscal-Labrador E, Cuberas-Borros G, Sabate-Fernandez M, Pizzi MN, Kisiel-Gonzalez N, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Daou D, Tawileh M, Coaguila C, De Araujo Goncalves P, Sousa PJ, Marques H, O'neill J, Pisco J, Cale R, Brito J, Gaspar A, Machado FP, Roquette J, Alexanderson Rosas E, Jimenez-Santos M, Martinez M, Melendez G, Kimura E, Romero E, Pena-Cabral MA, Jacome R, Ochoa JM, Meave A, Alessio AM, Patel A, Lautamaki R, Bengel FM, Bassingthwaighte JB, Caldwell JH, Rahbar K, Seifarth H, Schafers M, Stegger L, Spieker T, Hoffmeier A, Maintz D, Scheld H, Schober O, Weckesser M, Aoki H, Matsunari I, Kajinami K, Martin Fernandez M, Barreiro Perez M, Fernandez Cimadevilla OV, Leon Duran D, Velasco Alonso E, Florez Munoz JP, Luyando LH, Ghadri JR, Pazhenkottil AP, Nkoulou RN, Husmann L, Buechel RR, Herzog BA, Wolfrum M, Gaemperli O, Templin C, Kaufmann PA, De Graaf FR, Schuijf JD, Veltman CE, Van Velzen JE, Kroft LJ, De Roos A, Reiber JHC, Jukema JW, Van Der Wall EE, Bax JJ, Venuraju S, Yerramasu A, Atwal S, Lahiri A, Kunimasa T, Shiba M, Ishii K, Aikawa J, Van Velzen JE, Schuijf JD, De Graaf FR, Kroner ESJ, Kroft LJ, De Roos A, Schalij MJ, Jukema JW, Van Der Wall EE, Bax JJ, Pontone G, Andreini D, Bertella E, Mushtaq S, Formenti A, Annoni AD, Ballerini G, Fiorentini C, Bartorelli AL, Pepi M, Ho KT, Yong QW, Chua KC, Panknin C, Roos CJ, Van Werkhoven JM, Schuijf JD, Van Velzen JE, Witkowska-Grzeslo AJ, Boogers MJ, Kroft LJ, De Roos A, Jukema JW, Bax JJ, Yerramasu A, Venuraju S, Anand DV, Atwal S, Dey D, Berman D, Lahiri A, De Graaf FR, Schuijf JD, Veltman CE, Van Werkhoven JM, Van Velzen JE, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Bax JJ, Mut F, Giubbini R, Lusa L, Massardo T, Iskandrian A, Dondi M, Sato A, Kakefuda Y, Ojima E, Adachi T, Atsumi A, Ishizu T, Seo Y, Hiroe M, Aonuma K, Kruk M, Pracon R, Kepka C, Pregowski J, Kowalewska A, Pilka M, Opolski M, Michalowska I, Dzielinska Z, Demkow M, Stoll V, Sabharwal N, Chakera A, Ormerod O, Fernandes H, Bernardes M, Martins E, Oliveira P, Vieira T, Terroso G, Oliveira A, Faria T, Ventura F, Pereira J, Fukuzawa S, Inagaki M, Sugioka J, Ikeda A, Okino S, Maekawa J, Uchiyama T, Kamioka N, Ichikawa S, Afshar M, Alvi R, Aguilar N, Ippili R, Shaqra H, Bella J, Bhalodkar N, Dos Santos A, Daicz M, Cendoya LO, Marrero HG, Casuscelli J, Embon M, Vera Janavel G, Duronto E, Gurfinkel EP, Cortes CM, Takeishi Y, Nakajima K, Yamasaki Y, Nishimura T, Hayes Brown K, Collado F, Alhaji M, Green J, Alexander S, Vashistha R, Jain S, Aldaas F, Shanes J, Doukky R, Ashikaga K, Akashi YJ, Uemarsu M, Kamijima R, Yoneyama K, Omiya K, Miyake Y, Brodov Y, Venuraju S, Yerramasu A, Raval U, Lahiri A, Berezin A, Seden V, Koretskaya E, Berezin A, Panasenko TA, Matsuo S, Nakajima K, Kinuya S, Veltman CE, Boogers MJ, Chen J, Delgado V, Van Bommel RJ, Van Der Hiel B, Dibbets-Schneider P, Van Der Wall EE, Garcia EV, Bax JJ, Rutten-Vermeltfoort I, Gevers MMJ, Verhoeven B, Dijk Van AB, Raaijmakers E, Raijmakers PGHM, Engvall JE, Gjerde M, De Geer J, Olsson E, Quick P, Persson A, Mazzanti M, Marini M, Pimpini L, Perna GP, Marciano C, Gargiulo P, Galderisi M, D'amore C, Savarese G, Casaretti L, Paolillo S, Cuocolo A, Perrone Filardi P, Thompson RC, Al-Amoodi M, Thompson EC, Kennedy K, Bybee KA, Mcghie AI, O'keefe JH, Bateman TM, Van Der Palen RLF, Mavinkurve-Groothuis AM, Bulten B, Bellersen L, Van Laarhoven HWM, Kapusta L, De Geus-Oei LF, Pollice PP, Bonifazi MB, Pollice FP, Clements IP, Hodge DO, Scott CG, Daou D, Tawileh M, Coaguila C, De Ville De Goyet M, Brichard B, Pirotte T, Moniotte S, Tio RA, Elvan A, Dierckx RAIO, Slart RHJA, Furuhashi T, Moroi M, Hase H, Joki N, Masai H, Kunimasa T, Nakazato R, Fukuda H, Sugi K, Kryczka K, Kaczmarska E, Kepka C, Dzielinska Z, Petryka J, Mazurkiewicz L, Kruk M, Pregowski J, Demkow M, Ruzyllo W, Smanio P, Vieira Segundo E, Siqueira M, Kelendjian J, Ribeiro J, Alaca J, Oliveira M, Alves F, Peovska I, Maksimovic J, Vavlukis M, Kostova N, Pop Gorceva D, Majstorov V, Zdraveska M, Hussain S, Djearaman M, Hoey E, Morus L, Erinfolami O, Macnamara A, Kepka C, Kruk M, Pregowski J, Opolski MP, Pracon R, Michalowska I, Ruzyllo W, Witkowski A, Demkow M, Berti V, Ricci F, Gallicchio R, Acampa W, Cerisano G, Vigorito C, Sciagra' R, Pupi A, Cuocolo A, Nasr GM, Sliem H, Collado FM, Alhaji M, Schmidt S, Maheshwari A, Kiriakos R, Hayes Brown K, Vashistha R, Mwansa V, Shanes J, Doukky R, Ljubojevic S, Sedej S, Holzer M, Marsche G, Marijanski V, Kockskaemper J, Pieske B, Alexanderson Rosas E, Jacome R, Jimenez-Santos M, Romero E, Pena-Cabral MA, Ochoa JM, Ricalde A, Alexanderson G, Meave A, Mohani A, Khanna P, Liu Y, Sinusas A, Lee F, Pinas VA, Van Eck-Smit BLF, Verberne HJ, Lammertsma AA, De Bruin CM, Windhorst AD, Pena H, Guilhermina G, Wilk M, Srour Y, Godinho F, Jimenez-Angeles L, Ruiz De Jesus O, Yanez-Suarez O, Vallejo E, Reyes E, Chan M, Hossen ML, Underwood SR, Karu A, Bokhari S, Aguade-Bruix S, Cuberas-Borros G, Pineda V, Gracia-Sanchez LM, Pizzi MN, Garcia-Burillo A, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Zavadovskiy K, Lishmanov YU, Saushkin W, Kovalev I, Chernishov A, Pontone G, Andreini D, Cortinovis S, Bertella E, Mushtaq S, Annoni A, Formenti A, Bartorelli AL, Fiorentini C, Pepi M, Tarkia M, Saraste A, Saanijoki T, Oikonen V, Savunen T, Green MA, Strandberg M, Teras M, Knuuti J, Roivainen A, Gaeta MC, Fernandez Y, Artigas C, Deportos J, Geraldo L, Flotats A, La Delfa V, Carrio I, Wong YY, Lubberink M, Ruiter G, Knaapen P, Raijmakers P, Laarse WJ, Vonk-Noordegraaf A, Izquierdo Gomez MM, Lacalzada Almeida J, Barragan Acea A, De La Rosa Hernandez A, Juarez Prera R, Blanco Palacios G, Bonilla Arjona JA, Jimenez Rivera JJ, Iribarren Sarrias JL, Laynez Cerdena I, Dedic A, Rossi A, Ten Kate GJR, Dharampal A, Moelker A, Galema TW, Mollet N, De Feyter PJ, Nieman K, Andreini D, Pontone G, Mushtaq S, Formenti A, Bertella E, Annoni A, Ballerini G, Fiorentini C, Pepi M, Andreini D, Pontone G, Mushtaq S, Bartorelli AL, Trabattoni D, Bertella E, Annoni A, Formenti A, Fiorentini C, Pepi M, Broersen A, Frenay M, Boogers MM, Kitslaar PH, Van Velzen JE, Schuijf JD, Dijkstra J, Bax JJ, Reiber JHC, Pontone G, Andreini D, Mushtaq S, Bertella E, Annoni DA, Muratori M, Fusari M, Ballerini G, Bartorelli AL, Pepi M, Masai H, Moroi M, Johki N, Kunimasa T, Tokue M, Nakazato R, Furuhashi T, Fukuda H, Hase H, Sugi K, Dharampal AS, Weustink AC, Rossi A, Neefjes LAE, Papadopoulou SL, Chen C, Mollet NRA, Boersma EH, Krestin GP, De Feyter PJ, Purvis JA, Sharma D, Hughes SM, Zafrir N, Maddahi J, Berman DS, Taillefer R, Udelson J, Devine M, Lazewatsky J, Bhat G, Washburn D, Yerramasu A, Patel D, Mazurek T, Tandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F, Fukuda H, Moroi M, Masai H, Kunimasa T, Nakazato R, Furuhashi T, Sugi K, Harbinson MT, Wells G, Dougan J, Borges-Neto S, Phillips H, Farzaneh-Far A, Starr Z, Shaw LK, Fiuzat M, O'connor C, Henzlova M, Duvall WL, Levine A, Baber U, Croft L, Sahni S, Sethi S, Hermann L, Allam AH, Wann LS, Thompson RC, Nureldin A, Gomaa A, Badr I, Soliman MAT, Hany HAR, Sutherland ML, Thomas GS, Yiu KH, Schuijf J, Van Werkhoven JM, De Graaf F, Pazhenkottil A, Jukema JW, Bax JJ, De Roos A, Kroft LJ, Kaufmann PA, Kroner ESJ, Van Velzen JE, Boogers MJ, Siebelink HMJ, Schalij MJ, Kroft LJ, De Roos A, Reiber JH, Schuijf JD, Bax JJ, Ayub M, Naveed T, Azhar M, Van Tosh A, Faber TL, Votaw JR, Reichek N, Pulipati B, Palestro C, Nichols KJ, Einstein AJ, Khawaja T. Abstracts. Eur Heart J Suppl 2011. [DOI: 10.1093/eurheartj/sur013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
8
|
Frenay M, Burel-Vandenbos F, Met-Domestici M, Nasca L, Sobol H, Lebrun C. Association of anaplastic oligodendroglioma and BRCA1 mutation in males: Importance of clinical reflection and counseling. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e12001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Taillia H, Frappaz D, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Guillevin R, Skrzypski J, Dabakuyo TS, Chinot OL. Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Gronier S, Bourg V, Frenay M, Cohen M, Mondot L, Thomas P, Lebrun C. Le bévacizumab dans le traitement des radionécroses cérébrales. Rev Neurol (Paris) 2011; 167:331-6. [DOI: 10.1016/j.neurol.2010.10.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2010] [Revised: 07/16/2010] [Accepted: 10/15/2010] [Indexed: 11/30/2022]
|
11
|
Stupp R, Tosoni A, Bromberg JEC, Hau P, Campone M, Gijtenbeek J, Frenay M, Breimer L, Wiesinger H, Allgeier A, van den Bent MJ, Bogdahn U, van der Graaf W, Yun HJ, Gorlia T, Lacombe D, Brandes AA. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 2011; 22:2144-2149. [PMID: 21321091 PMCID: PMC3164435 DOI: 10.1093/annonc/mdq729] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Background: Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood–brain barrier has demonstrated preclinical activity in glioma models. Patients and methods: Patients with first recurrence/progression of glioblastoma were eligible for this early phase II and pharmacokinetic study exploring single-agent sagopilone (16 mg/m2 over 3 h every 21 days). Primary end point was a composite of either tumor response or being alive and progression free at 6 months. Overall survival, toxicity and safety and pharmacokinetics were secondary end points. Results: Thirty-eight (evaluable 37) patients were included. Treatment was well tolerated, and neuropathy occurred in 46% patients [mild (grade 1) : 32%]. No objective responses were seen. The progression-free survival (PFS) rate at 6 months was 6.7% [95% confidence interval (CI) 1.3–18.7], the median PFS was just over 6 weeks, and the median overall survival was 7.6 months (95% CI 5.3–12.3), with a 1-year survival rate of 31.6% (95% CI 17.7–46.4). Maximum plasma concentrations were reached at the end of the 3-h infusion, with rapid declines within 30 min after termination. Conclusions: No evidence of relevant clinical antitumor activity against recurrent glioblastoma could be detected. Sagopilone was well tolerated, and moderate-to-severe peripheral neuropathy was observed in despite prolonged administration.
Collapse
Affiliation(s)
- R Stupp
- Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
| | - A Tosoni
- Department of Medical Oncology, Bellaria Maggiore Hospital, Bologna, Italy
| | - J E C Bromberg
- Department of Neuro-Oncology, Daniel den Hoed Cancer Center/Erasmus University Hospital, Rotterdam, The Netherlands
| | - P Hau
- Department of Neurology, University of Regensburg Medical School, Regensburg, Germany
| | - M Campone
- Department of Medical Oncology, Institut Régional du Cancer Nantes Atlantique, CLCC René Gauducheau, Centre de Recherche en Cancérologie, St Herblain, France
| | - J Gijtenbeek
- Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - M Frenay
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice Cedex, France
| | | | | | | | - M J van den Bent
- Department of Neuro-Oncology, Daniel den Hoed Cancer Center/Erasmus University Hospital, Rotterdam, The Netherlands
| | - U Bogdahn
- Department of Neurology, University of Regensburg Medical School, Regensburg, Germany
| | - W van der Graaf
- Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - H J Yun
- EORTC Headquarters, Brussels, Belgium
| | - T Gorlia
- EORTC Headquarters, Brussels, Belgium
| | - D Lacombe
- EORTC Headquarters, Brussels, Belgium
| | - A A Brandes
- Department of Medical Oncology, Bellaria Maggiore Hospital, Bologna, Italy
| |
Collapse
|
12
|
|
13
|
Abstract
BACKGROUND AND PURPOSE We review the indications and limitations of chemotherapy in glioblastoma multiform (GBM), including the role played by alkylating and other cytotoxic agents and the increased input of clinical research on targeted agents in GBM management. METHODS In 2005, a phase III study clearly concluded in the benefit of adding temozolomide during and after radiotherapy treatment in GBM and thus defined the new standard of treatment in this devastating disease. This schedule increased the median survival from 12.1 to 14 months and the two- and five-year survival rates from 8 to 26%, and 3 to 10%, respectively, with a good tolerance profile. Moreover, methylation of the promoter of the O6 methylguanine DNA transferase (MGMT) gene exhibits a prognostic impact independently of therapeutic schedule but may also predict the benefit of adding temozolomide to radiotherapy. However, pitfalls in MGMT determination and lack of prospective validation have to be solved before considering MGMT as a decisional marker. More recently, antiangiogenic agents including enzastaurin, cediranib, bevacizumab, and others that target mainly the VEGF pathway, have been evaluated in this highly angiogenic disease. Among them, only bevacizumab has been associated with clear anti-tumor activity, although the lack of control studies limits the impact of the results to date. CONCLUSIONS Recent studies conducted in GBM, both in the adjuvant and recurrent setting, have changed the natural course of the disease and opened a new area of clinical research, including imaging and response evaluation, predictive markers, and other targeted therapies.
Collapse
Affiliation(s)
- O Chinot
- Service de neuro-oncologie, CHU Timone, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France.
| | | | | |
Collapse
|
14
|
Marcy P, Chamorey E, Figl A, Frenay M, Peyrade F, Largillier R, Machiavello J, Ferrero J, Francois E, Thariat J. Venous thrombosis associated with central venous catheter in cancer patients with surgical chest port (S) or venography- guided arm port insertion (R): A randomized controlled study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9158] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Lebrun C, Frenay M. Complications neurologiques des chimiothérapies. Rev Med Interne 2010; 31:295-304. [DOI: 10.1016/j.revmed.2009.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2008] [Revised: 09/30/2009] [Accepted: 12/18/2009] [Indexed: 11/30/2022]
|
16
|
Pallud J, Mandonnet E, Fontaine D, Duffau H, Capelle L, Bauchet L, Peruzzi P, Jouanneau E, Page P, Bozec-Le Moal L, Frenay M, Delattre JY, Cartalat-carel S, Aldea S, Taillandier L. La grossesse modifie l’histoire naturelle des gliomes diffus de grade II OMS. Approche quantitative de l’évolution de la croissance radiologique. Neurochirurgie 2009. [DOI: 10.1016/j.neuchi.2009.08.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Marcy P, Chamorey E, Macchiavello J, Largillier R, Peyrade F, Ferrero J, Hanoun-Levi J, Poudenx M, François E, Frenay M. Distal or proximal venous port device insertion: Results of a prospective randomized trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20605 Background: Open, nonblinded, prospective, randomized, controlled trial comparing two techniques of venous port device insertion: percutaneous distal (phlebography-guided arm port- study technique- 2) vs proximal surgical (cephalic vein cutdown- control technique- 1) placement -To determine whether technique 1 is superior to technique 2. Methods: 230 eligible patients beginning a course of i.v. chemotherapy via a port device catheter with an expected duration of treatment of 3 months or longer were randomized (written informed consent). Eligibility criteria included adult patients with solid tissue malignancy (neuro oncology, gynecology, lung, abdominal, head§neck) beginning a course of I.V.chemotherapy, normal hemostatic parameters, no organ failure, a life expectancy >3months, WHO status<3. Exclusion criteria included current anticoagulant therapy, previous ipsilateral venous catheter/pacewires/surgical axillary node dissection/radiodermatitis, local tumor growth/sepsis, symptomatic brain metastasis, psychosis. The silicone rubber 7F catheter was connected to a 11mm port reservoir, and implanted under local anesthesia using either technique 1 or 2 after randomization. Outcome measurements included technical feasibility/procedure duration, port complications, quality of life (EORTC) questionnaires. Results: Median study duration was 12.2 vs 11.9 months (p: 0.9), median chemotherapy cycles were 6.0 in both groups. Patients groups differed significantly in venous access side (left access in group 2) and sex ratio (p=0.028). In group 2, technical success rate was higher (99 vs 91%, p<0.02), procedure was shorter: 18.0min (10.0–90.0) vs 21min (15.0- 45.0)(p<0.008), but global complication rate was higher (p<0.05). Device complication related explantation rate was 11.9 vs 2.8% (p=0.022). Conclusions: Both techniques are safe and effective. Despite a higher technical success rate and a shorter procedure duration, arm port insertion has a lower complication-free duration. Distal (arm port) technique should be recommended in young female cancer patients (neckline cosmesis/discretion), head and neck cancer patients, obese patients (upright position) and in patients presenting with respiratory insufficiency or at high risk for pneumothorax. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Marcy
- Antoine Lacassagne, Nice, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Bondiau PY, Konukoglu E, Clatz O, Frenay M, Delingette H, Ayache N. Bioinformatique : comparaison des marges d’irradiation conventionnelles avec un modèle de croissance tumoral numérique. Cancer Radiother 2008. [DOI: 10.1016/j.canrad.2008.08.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice]. Rev Neurol (Paris) 2008; 164:595-604. [PMID: 18565359 DOI: 10.1016/j.neurol.2008.04.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2008] [Revised: 04/08/2008] [Accepted: 04/09/2008] [Indexed: 11/17/2022]
Abstract
Losses of chromosomes 1p and 19q are deemed correlated with diagnosis of oligodendroglioma, higher chemosensitivity and better prognosis. We reviewed the literature to evaluate the usefulness of these correlations in daily clinical practice. The rates of deletions relative to histology (WHO classifications) were extracted from 33 studies, including 2666 patients. The 1p deletions and 1p19q codeletion mean rates were respectively 65.4 and 63.3% in oligodendrogliomas, 28.7 and 21.6% in oligoastrocytomas, 13.2 and 7.5% in astrocytomas, 11.6 and 2.9% in glioblastomas. The presence of 1p deletion and 1p19q codeletion were strongly correlated with the histological diagnosis corresponding to oligodendroglioma. Calculation of specificity, sensitivity, predictive positive values and false negative rates suggests that presence of deletion 1p or codeletion represents a strong argument in favor of the diagnosis of oligodendroglioma. However, considering the high false negative rate, absence of such deletions does not rule out the diagnosis. In grade 3 oligodendroglial tumors, the probability of responding to chemotherapy, and the duration of response, were higher when codeletions were present. This suggests that, in these tumors, the presence of codeletion is a strong argument in favor of adjuvant chemotherapy. However, chemotherapy should not be systematically excluded when codeletions are absent, as the chances of response are about 33% in this situation. Data concerning low-grade gliomas were more controversial. Oligodendroglial tumors with 1p deletion or 1p19q codeletion seemed to have a better prognosis, as five-year survival rates were 50% higher than in tumors without deletion. This might be explained by the correlation between 1p deletion and other identified prognosis factors: (1) higher chemosensitivity, (2) tumor location more frequently in the frontal lobe, leading to better resection and lower risk of neurological deficit, (3) slower growth rate, (4) higher risk of epilepsy, leading to an early detection.
Collapse
Affiliation(s)
- D Fontaine
- Service de neurochirurgie, hôpital Pasteur, CHU de Nice, UNSA, 30, avenue de la Voie-Romaine, 06000 Nice, France.
| | | | | | | | | |
Collapse
|
20
|
Chamorey E, Lebrun C, Fontaine D, Vandenbos F, Michiels J, Paquis P, Frenay M. General epidemiology and survival rate of malignant and non-malignant brain and central nervous system tumors in Nice area (France). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.17078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17078 Background: The aim of this cohort study was to produce descriptive epidemiological data from the Group of Neuro- Oncology of Nice (GNON) database. Data were collected from the Comprehensive Cancer Center and the University Hospital of Nice (France). Methods: All cases that have been discussed during multidisciplinary meetings of neuro-oncology were entered. Data were compared with the Central Brain Tumor Registry of the United States (CBTRUS) report taken as reference tool. Follow-up information was obtained from the patient medical chart and from the national death registry. Results: 1,395 patients (718 males, 677 females) were registered in the data base. There were 938 tumors of neuroepithelial tissue (percentage of all reported cases in our study: 67.9%, median age in our study; 58 yrs, percentage in CBTRUS report: 43.6%, median age in CBTRUS report: 53 yrs), 55 tumors of cranial and spinal nerves (4.0%, 53 yrs; 8%, 52 yrs), 270 tumors of meninges (19.5%, 59 yrs; 31.4%, 63 yrs), 54 lymphoma and hemopoietic neoplasm (3.9%, 68 yrs; 3.1%, 60 yrs), 16 germ cell tumors, cysts and heterotopias (1.2%, 17yrs; 0.6%, 16yrs), 12 craniopharyngioma (0.9%, 50 yrs; 0.7%, 48 yrs), 9 chordoma/chondrosarcoma (0.6%, 65 yrs; 0.2%, 48 yrs), 27 unclassified tumors (2.0%, 46 yrs; 6.1%, 68 yrs). The table shows the survival rates at one, three and five years respectively for some selected brain and central nervous system tumors (results from the CBTRUS report in parentheses). Conclusions: A comparison between results from the CBTRUS and GNON data base showed some similarities and didn't point out any major unexplainable discrepancy. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Chamorey
- Centre Antoine Lacassagne, Nice, France; University Hospital, Nice, France
| | - C. Lebrun
- Centre Antoine Lacassagne, Nice, France; University Hospital, Nice, France
| | - D. Fontaine
- Centre Antoine Lacassagne, Nice, France; University Hospital, Nice, France
| | - F. Vandenbos
- Centre Antoine Lacassagne, Nice, France; University Hospital, Nice, France
| | - J. Michiels
- Centre Antoine Lacassagne, Nice, France; University Hospital, Nice, France
| | - P. Paquis
- Centre Antoine Lacassagne, Nice, France; University Hospital, Nice, France
| | - M. Frenay
- Centre Antoine Lacassagne, Nice, France; University Hospital, Nice, France
| |
Collapse
|
21
|
Abstract
Turcot syndrome is clinically characterized by the occurrence of primary brain tumor and colorectal tumor and has, in previous reports, been shown associated with germline mutations in the genes APC, MLH1, MHS6, and PMS2. To date, only few families have been documented by molecular analysis. We report two new families with Turcot syndrome to illustrate and review its characteristics and facilitate diagnosis. Molecular analysis revealed two germline mutations, one in the MLH1 gene and one in MSH2. The latter has never been describe in the literature. Personal and familial relevant anamnestic data from patients with glioma might aid in the diagnosis of genetic disorders. The subsequent molecular characterization may contribute to the appropriate care of affected patients and asymptomatic gene carriers.
Collapse
Affiliation(s)
- C Lebrun
- Service de Neurologie, Hôpital Pasteur, Nice, France.
| | | | | | | | | | | |
Collapse
|
22
|
Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 2007; 14:391-8. [PMID: 17388986 DOI: 10.1111/j.1468-1331.2007.01675.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed. Several studies have reported the efficacy of various chemotherapeutic agents in a small number of patients with low-grade gliomas, e.g. pure astrocytomas, OG or mixed histologies. The 5-year survival rate varies from 61% to 89% with a mean time to progression of 5 years. We report the outcome of 33 consecutive patients with pure low-grade OG diagnosed between 1990 and 2006 systematically treated for residual or non-removable tumor with PCV chemotherapy regimen as the front-line treatment after surgery. All the tumors were low grade (grade II) pure OG according to the WHO classification. All patients were symptomatic at presentation and underwent neurosurgical procedure for histological diagnosis. Response was evaluated by clinical assessment and brain magnetic resonance imaging. Twenty-one men and 12 women with a mean age at pathological diagnosis of 46.5 years were studied. The most common first symptom was partial epileptic seizure (73.7%). Six patients (18%) had initial gadolinium enhancement, associated with methoxyisobutyl (MIBI) hypermetabolism (P < 0.001). The resection was partial in seven cases (21%), and 26 patients (79%) had biopsy only. Eleven patients (36%) had a malignant transformation during the follow-up with a median time to progression of 19 months. Favorable prognostic factors were lack of contrast enhancement (P < 0.0001), and age <40 years (P < 0.0003); 90% of patients were progression-free at 1 year. Survival rates at 2, 5 and 10 years were 85%, 75% and 50%, respectively. Up-front chemotherapy with PCV regimen is a good treatment for symptomatic pure low-grade OG, as it increases the number of progression-free patients and time to progression. These results suggest that radiotherapy could be postponed until the malignant transformation occurs to delay cognitive side effects of irradiation.
Collapse
Affiliation(s)
- C Lebrun
- Department of Neurology, Hôpital Pasteur, Nice, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Mari V, Chamorey E, Italiano A, Van Den Bos F, Ferri-Dessens R, Ferrero J, Largillier R, Ettore F, Courdi A, Paquis P, Frenay M. Clinical significance of brain metastases occurrence in HER2 overexpressing metastatic breast cancer patients treated with trastuzumab. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10593 Background: Recent data report that HER2 overexpressing metastatic breast cancer patients (HER+ MBC pts) treated with trastuzumab (T) have a high rate of Brain metastasis (BM). This study aimed to evaluate the prognostic significance of BM occurrence and the related clinical outcome in a specific patient population. Methods: All the HER+MBC patients treated with trastuzumab (with or without chemotherapy) between 09/1999 and 12/2004 were included in this study. Results: A total of forty three patients were enrolled into the study cohort. The median follow-up was 48 months (range, 11–166). Fifteen patients (35%) developped BM. The median interval from the the first MBC event to BM was 18 months (range, 1–65). In multivariate analysis; younger age was the only factor associated with BM occurrence (46 versus 57 years; p = 0.01). Patients with BM tend to have a longer median duration of response to T than patients without BM (16 months versus 13 months; p = 0.1). At the time of BM appearance, 6 of the 15 patients (40%) were still responding or had achieved extracranial stable disease while receiving trastuzumab. Twelve out of 15 (80%) pts received a whole-brain radiation therapy, and 8 pts continued to receive trastuzumab until extracranial disease progression. The median overall survival for patients diagnosed with BM was 10 months (range, 2–42). At three-year, there was no significant difference in overall survival rates between the two groups. The 3-YS was 63.5% and 66.7% for pts with or without BM, respectively; (p = 0.7). Conclusions: The BM occurrence in HER2+ MBC pts treated with Trastuzumab is not linked to tumour resistance, but likely related to the T inability to cross the blood-brain barrier. There is no impaired survival for these pts treated with effective and appropriate therapy. [Table: see text]
Collapse
Affiliation(s)
- V. Mari
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - E. Chamorey
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - A. Italiano
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - F. Van Den Bos
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - R. Ferri-Dessens
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - J. Ferrero
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - R. Largillier
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - F. Ettore
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - A. Courdi
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - P. Paquis
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| | - M. Frenay
- Centre Antoine Lacassagne, Nice, France; Centre Hospitalo-Universitaire, Nice, France; Laboratoire Roche, Neuilly, France
| |
Collapse
|
24
|
Abstract
INTRODUCTION Turcot's syndrome is characterized clinically by the concurrence of a primary brain tumor and a familial adenomatous polyposis or a hereditary nonpolyposis colorectal cancer. OBSERVATION We report a case of a 45-year-old woman who underwent in 1995 neuro-oncological treatment for an anaplastic astrocytoma (grade III according to the World Health Organization classification). Treatment included complete surgery, radiotherapy, a first-line nitrosourea-based chemotherapy regimen and a second-line platinium salt-based regimen. It was then noted that the patient's brother had colorectal cancer. A genetic study detected a germ-line mutation on the hMSH2 gene specific of HNPCC syndrome (Human Non Polyposis Colorectal Cancer). Colonoscopy was normal. Eight years after the diagnosis, the patient developed a gliomatosis cerebri and died. CONCLUSION Relevant personal and familial history can provide the clue to the diagnosis of Turcot's syndrome. Molecular diagnosis may contribute to appropriate care of affected patients.
Collapse
Affiliation(s)
- S Jeannin
- Service de Neurologie, Hôpital Pasteur, Nice
| | | | | | | | | | | |
Collapse
|
25
|
van den Bent MJ, Delattre JY, Brandes AA, Taphoorn MJB, Hoang Xuan K, Bernsen H, Frenay M, Grisold W, Gorlia T, Lacombe D. First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1503] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. J. van den Bent
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - J.-Y. Delattre
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - A. A. Brandes
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - M. J. B. Taphoorn
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - K. Hoang Xuan
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - H. Bernsen
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - M. Frenay
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - W. Grisold
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - T. Gorlia
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| | - D. Lacombe
- Daniel den Hoed Oncology Ctr, Rotterdam, The Netherlands; Federation de Neurologie Mazarin, Groupe Hospitalier Pitié Salpetriere, Paris, France; Azienda Ospedale-Universita of Padova, Padova, Italy; Medisch Centrum Haaglanden, The Hague, The Netherlands; Canisius Wilhemina Ziekenhuis, Nijmegen, The Netherlands; Ctr Antoine Lacassagne, Nice, France; Kaiser Frans Joseph Spital, Vienna, Austria; EORTC Datacenter, Brussels, Belgium
| |
Collapse
|
26
|
van den Bent M, Brandes A, Frenay M, Fumoleau P, Stupp R, Dittrich C, Coudert B, Clement P, Lacombe D, Raymond E. Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1517] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - A. Brandes
- EORTC NDDG/BTG/Data Ctr, Brussels, Belgium
| | - M. Frenay
- EORTC NDDG/BTG/Data Ctr, Brussels, Belgium
| | | | - R. Stupp
- EORTC NDDG/BTG/Data Ctr, Brussels, Belgium
| | | | - B. Coudert
- EORTC NDDG/BTG/Data Ctr, Brussels, Belgium
| | - P. Clement
- EORTC NDDG/BTG/Data Ctr, Brussels, Belgium
| | - D. Lacombe
- EORTC NDDG/BTG/Data Ctr, Brussels, Belgium
| | - E. Raymond
- EORTC NDDG/BTG/Data Ctr, Brussels, Belgium
| |
Collapse
|
27
|
Lonjon M, Lebrun C, Vandenbos F, Fontaine D, Frenay M, Paquis P, Grellier P. Oligodendrogliomes : analyse retrospective d’une série de 120 patients. Neurochirurgie 2004. [DOI: 10.1016/s0028-3770(04)98352-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, Michiels JF, Bourg V, Paquis P, Chatel M, Frenay M. Long-term outcome of oligodendrogliomas. Neurology 2004; 62:1783-7. [PMID: 15159478 DOI: 10.1212/01.wnl.0000125196.88449.89] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Favorable prognostic factors for oligodendroglial tumors include age younger than 40 years, low tumor grade, and extent of resection. OBJECTIVE To assess survival time and prognostic factors of 100 patients with oligodendrogliomas diagnosed between 1995 and 2002. METHODS The tumors were rated histologically by the WHO classification as low grade (grade II) or anaplastic (grade III). One hundred patients were categorized into three groups: group A: grade II, group B: secondary grade III (low grade with anaplastic transformation during the follow-up), group C: de novo grade III. All patients were symptomatic at presentation and underwent neurosurgical procedure for histologic diagnosis. Follow-up was performed with clinical assessment, brain MRI, and MIBI scintigraphy. RESULTS There were 66 men and 34 women (mean age at diagnosis 46.7 years). The most common first symptom was partial epileptic seizure (75%). Fifty-six patients had initial gadolinium enhancement (A: 15.6%; B: 36.8% as grade II, 95% as grade III; C: 90%), generally associated with MIBI hypermetabolism (p < 0.0001). Survival rates at 2, 5, and 10 years were A: 88%, 88%, 85%; B: 79%, 64%, 42%; C: 43%, 16%, 15%. CONCLUSIONS Secondary anaplastic oligodendroglioma patients were younger than patients with de novo anaplastic oligodendrogliomas. Histologic confirmation is mandatory because some low grade oligodendrogliomas had gadolinium enhancement on MRI and some anaplastic did not. Survival time was longer for secondary than for de novo anaplastic oligodendrogliomas without difference in the duration of the malignant phase of the disease.
Collapse
Affiliation(s)
- C Lebrun
- Department of Neurology, Hôpital Pasteur, Nice, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Triebels VHJM, Taphoorn MJB, Brandes AA, Menten J, Frenay M, Tosoni A, Kros JM, Stege EBT, Enting RH, Allgeier A, van Heuvel I, van den Bent MJ. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 2004; 63:904-6. [PMID: 15365146 DOI: 10.1212/01.wnl.0000137049.65631.db] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma. The genotype of the tumors was assessed with fluorescent in situ hybridization with locus specific probes for the region 1p36. Four of the 24 patients responded (17%). Fifty percent of patients were still free from progression at 6 months and 21% were free from progression at 12 months. Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy.
Collapse
MESH Headings
- Adult
- Antineoplastic Agents, Alkylating/pharmacology
- Antineoplastic Agents, Alkylating/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Astrocytoma/drug therapy
- Astrocytoma/genetics
- Brain Neoplasms/drug therapy
- Brain Neoplasms/genetics
- Chromosomes, Human, Pair 1/genetics
- Chromosomes, Human, Pair 1/ultrastructure
- Chromosomes, Human, Pair 19/genetics
- Chromosomes, Human, Pair 19/ultrastructure
- Cohort Studies
- Dacarbazine/analogs & derivatives
- Dacarbazine/pharmacology
- Dacarbazine/therapeutic use
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Female
- Humans
- Lomustine/administration & dosage
- Male
- Middle Aged
- Oligodendroglioma/drug therapy
- Oligodendroglioma/genetics
- Procarbazine/administration & dosage
- Remission Induction
- Retrospective Studies
- Salvage Therapy
- Sequence Deletion
- Temozolomide
- Treatment Outcome
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- V H J M Triebels
- Department of Neuro-Oncology, Erasmus MC, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Frenay M, Ramaioli A, Fontaine D, Bourg V, Vandenbos F, Lebrun C. Prognostic factors of oligodendrogliomas. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Frenay
- Centre Antoine Lacassagne, Nice, France; Hopital Pasteur, Nice, France
| | - A. Ramaioli
- Centre Antoine Lacassagne, Nice, France; Hopital Pasteur, Nice, France
| | - D. Fontaine
- Centre Antoine Lacassagne, Nice, France; Hopital Pasteur, Nice, France
| | - V. Bourg
- Centre Antoine Lacassagne, Nice, France; Hopital Pasteur, Nice, France
| | - F. Vandenbos
- Centre Antoine Lacassagne, Nice, France; Hopital Pasteur, Nice, France
| | - C. Lebrun
- Centre Antoine Lacassagne, Nice, France; Hopital Pasteur, Nice, France
| |
Collapse
|
31
|
van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich C, de Jonge MJA, Brandes A, Frenay M, Carpentier AF, Chollet P, Oliveira J, Baron B, Lacombe D, Schuessler M, Fumoleau P. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 2004; 14:1732-4. [PMID: 14630677 DOI: 10.1093/annonc/mdg491] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Glufosfamide is a new alkylating agent in which the active metabolite of isophosphoramide mustard is covalently linked to beta-D-glucose to target the glucose transporter system and increase intracellular uptake in tumor cells. We investigated this drug in a multicenter prospective phase II trial in recurrent glioblastoma multiforme (GBM). PATIENTS AND METHODS Eligible patients had recurrent GBM following surgery, radiotherapy and no more than one prior line of chemotherapy. Patients were treated with glufosfamide 5000 mg/m(2) administered as a 1-h intravenous infusion. Treatment success was defined as patients with either an objective response according to Macdonald's criteria or 6 months progression-free survival. Toxicity was assessed with the Common Toxicity Criteria (CTC) version 2.0. RESULTS Thirty-one eligible patients were included. Toxicity was modest, the main clinically relevant toxicities being leukopenia (CTC grade >3 in five patients) and hepatotoxicity (in three patients). No responses were observed; one patient (3%; 95% confidence interval 0 to 17%) was free from progression at 6 months. Pharmacokinetic analysis showed a 15% decrease in area under the curve and glufosfamide clearance in patients treated with enzyme-inducing antiepileptic drugs, but no effect of these drugs on maximum concentration and plasma half-life. CONCLUSION Glufosfamide did not show significant clinical antitumor activity in patients with recurrent GBM.
Collapse
Affiliation(s)
- M J van den Bent
- Department of Neuro-Oncology, Daniel den Hoed Cancer Center/Erasmus University Medical Center, Rotterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Chanalet S, Lebrun-Frenay C, Frenay M, Lonjon M, Chatel M. Symptomatologie clinique et diagnostic neuroradiologique des tumeurs intracrâniennes. ACTA ACUST UNITED AC 2004. [DOI: 10.1016/j.emcn.2003.10.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Lebrun C, Frenay M. [Chemotherapeutic neurotoxicity]. Rev Neurol (Paris) 2003; 159:741-54. [PMID: 13679716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/23/2023]
Abstract
Not uncommonly, damage to the nervous system occurs as a complication of antineoplastic therapy. Neurotoxicity can be induced by synergistic or additive effects of cytotoxic treatments and nervous system exposure is related to routes and doses. Improvements in treating systemic malignancy have been accompanied by reports of neurologic toxicity that has important impact on quality of life and may even limit use of the treatment. Neurological toxicity may be a dose-limiting factor that prevents more aggressive use of that form of treatment. With the increasing use of multi-modality therapy, dose-intensive therapy and experimental therapy, the incidence of neurological toxicity continues to rise. It points out the need for continuous clinical evaluation to detect their appearance. When neurological complications are diagnosed late, they are rarely reversible. Neuroprotective agents are still under evaluation.
Collapse
Affiliation(s)
- C Lebrun
- Service de Neurologie, CHU de Nice
| | | |
Collapse
|
34
|
Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21:2726-31. [PMID: 12860951 DOI: 10.1200/jco.2003.11.036] [Citation(s) in RCA: 216] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To assess the efficacy and toxicity of chemotherapy alone in patients older than 60 years with primary CNS lymphoma. PATIENTS AND METHODS Fifty patients with a median age of 72 years and a median Karnofsky performance score (KPS) of 50 were eligible for this multicenter phase II study. The protocol consisted of high-dose methotrexate (MTX), lomustine, procarbazine, methylprednisolone, and intrathecal chemotherapy with MTX and cytarabine. The patients received one induction cycle; if objective response was achieved, five additional maintenance cycles were administered every 6 weeks. The median follow-up of patients was 3 years. RESULTS Twenty four patients (48%) achieved an objective response (compete response [CR], 42%; partial response, 6%), with a median duration of CR of 27 months (range, 3 to 47+ months). Overall median survival time was 14.3 months, and 1-year progression-free survival was 40% (95% confidence interval [CI], 26% to 53%). Myelosuppression was the most frequent side effect, with grade 3 to 4 neutropenia in 19% of patients. One patient died during chemotherapy, as a result of pulmonary embolism. Most patients improved or preserved their cognitive functions (47% and 45% of the patients, respectively) and KPS (36% and 52% of the patients, respectively) until relapse, whereas cognitive and KPS decline attributed to delayed treatment neurotoxicity occurred in 8% and 12% patients, respectively. CONCLUSION In the elderly, this chemotherapy regimen compares favorably with radiotherapy (RT) alone and reduces considerably the risk of delayed neurotoxicity associated with combined chemoradiotherapy. Chemotherapy alone is an appropriate strategy in older patients to delay or avoid RT.
Collapse
Affiliation(s)
- K Hoang-Xuan
- Fédération Neurologique Mazarin, Groupe Hospitalier Pitié-Salpêtrière, 47 boulevard de l'hôpital, 75651 Paris Cedex 13, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
van den Bent MJ, Taphoorn MJB, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CCD, Vecht CJ, Allgeier A, Gorlia T. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21:2525-8. [PMID: 12829671 DOI: 10.1200/jco.2003.12.015] [Citation(s) in RCA: 242] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients responding to combination chemotherapy with procarbazine, lomustine, and vincristine (PCV). Temozolomide (TMZ), a new alkylating and methylating agent, has demonstrated high response rates in patients with recurrent anaplastic astrocytoma. We investigated TMZ as first-line chemotherapy in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after surgery and radiation therapy. PATIENTS AND METHODS In a prospective, nonrandomized, multicenter, phase II trial, patients were treated with 200 mg/m2 of TMZ on days 1 through 5 in 28-day cycles for 12 cycles. Patients with a recurrence after prior surgery and radiotherapy, and with measurable and enhancing disease on magnetic resonance imaging (MRI) were eligible for this study. Patients with large lesions and mass effect or with new clinical deficits were not eligible. Pathology and the MRI scans of all responding patients were centrally reviewed. RESULTS Thirty-eight eligible patients were included. In three patients, pathology review did not confirm the presence of an OD or OA. TMZ was generally well tolerated. The most frequent side effects were hematologic; only one patient discontinued treatment for toxicity. In 20 (52.6%) of 38 patients (95% exact confidence interval, 35.8% to 69.0%), a complete (n = 10) or partial response to TMZ was observed. The median time to progression was 10.4 months for all patients and 13.2 months for responding patients. At 12 months from the start of treatment, 40% of patients were still free from progression. CONCLUSION TMZ provides an excellent response rate with good tolerability in chemotherapy-naive patients with recurrent OD. A randomized phase III study comparing PCV with TMZ is warranted.
Collapse
Affiliation(s)
- M J van den Bent
- Department of Neuro-Oncology, University Hospital Rotterdam/Rotterdam Cancer Center, the Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, Faivre S, Sicard E, Germa C, Rodier JM, Vernillet L, Armand JP. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol 2003; 14:603-14. [PMID: 12649109 DOI: 10.1093/annonc/mdg159] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND To assess the antitumour activity and safety profile of irinotecan and its pharmacokinetic interactions with anticonvulsants in patients with glioblastoma multiforme. PATIENTS AND METHODS This multicentre phase II and pharmacokinetic study investigated the effects of irinotecan 350 mg/m(2) given as a 90-min infusion every 3 weeks either prior to (group A) or after relapse following radiotherapy (group B) in chemotherapy-naïve patients with glioblastoma. Preferred concomitant medication for seizure prevention was valproic acid. Pharmacokinetic analysis of irinotecan and its main metabolites (SN-38, SN-38-G, APC and NPC) was performed during cycle 1. An independent panel of experts reviewed the activity data. RESULTS Fifty-two patients (25 patients in group A and 27 patients in group B) received a total of 191 cycles of irinotecan. Forty-six patients (22 patients in group A and 24 patients in group B) were evaluable and externally reviewed for activity. According to external review, one partial response (group B), seven minor responses (three in group A and four in group B), 12 disease stabilisations (seven in group A and five in group B) were observed. This resulted in an overall response rate of only 2.2% (95% confidence interval 0.2% to 6.5%). The median time to tumour progression was 9 weeks in group A and 14.4 weeks in group B. Six-month progression-free survival rates were 26% in group A and 43% in group B. Grade 3-4 toxicities (percentage of patients in groups A and B) consisted of neutropenia (12.5% and 25.9%), diarrhoea (8.3% and 7.4%), asthenia (12.5% and 7.4%) and vomiting (0% and 7.4%). The clearance of irinotecan was 12.4 and 14.4 l/h/m(2) in two patients who received no anticonvulsant. In patients receiving valproic acid, the clearance of irinotecan was 17.2 +/- 4.4 l/h/m(2). CONCLUSIONS Irinotecan given at the dose of 350 mg/m(2) every 3 weeks has limited clinical activity as a single agent in patients with newly diagnosed and recurrent glioblastoma after radiotherapy. The toxicity profile and plasma disposition of irinotecan and SN-38 were not strongly influenced by anticonvulsant valproic acid therapy. Although the response rate of irinotecan as a single agent was limited, it remains an attractive drug for combination studies in patients with glioblastoma.
Collapse
Affiliation(s)
- E Raymond
- Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Schobel U, Frenay M, van Elswijk DA, McAndrews JM, Long KR, Olson LM, Bobzin SC, Irth H. High resolution screening of plant natural product extracts for estrogen receptor alpha and beta binding activity using an online HPLC-MS biochemical detection system. J Biomol Screen 2001; 6:291-303. [PMID: 11689129 DOI: 10.1177/108705710100600503] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A new screening technology that combines biochemical analysis with the resolution power of high-performance liquid chromatography (HPLC), referred to here as high-resolution screening (HRS) technique, is described. The capability of the HRS technology to analyze biologically active compounds in complex mixtures is demonstrated by screening a plant natural product extract library for estrogen receptor (ER) alpha and beta binding activity. The simultaneous structure elucidation of biologically active components in crude extracts was achieved by operating the HRS system in combination with mass spectrometry (MS). In contrast to conventional microtiter-type bioassays, the interactions of the extracts with the ER and the employed label, coumestrol, proceeded at high speed in a closed, continuous-flow reaction detection system, which was coupled directly to the outlet of a HPLC separation column. The reaction products of this homogeneous fluorescence enhancement-type assay were detected online using a flowthrough fluorescence detector. Primary screening of the extract library was performed in the fast-flow injection analysis mode (FlowScreening) wherein the chromatographic separation system was bypassed. The library was screened at high speed, using two assay lines in parallel. A total of 98% of the identified hits were confirmed in a traditional 96-well microplate-based fluorescence polarization assay, indicating the reliability of the FlowScreening process. Active extracts were reassayed in a transcriptional activation assay in order to assess the functional activity of the bioactive extracts. Only functional active extracts were processed in the more time-consuming HRS mode, which was operated in combination with MS. Information on the number of active compounds, their retention times, the molecular masses, and the MS/MS-fingerprints as a function of their biological activity was obtained from 50% of the functional active extracts in real time. This dramatically enhances the speed of biologically active compound characterization in natural product extracts compared to traditional fractionation approaches.
Collapse
Affiliation(s)
- U Schobel
- ScreenTec B.V., Leiden, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Marcy PY, Magné N, Frenay M, Bruneton JN. Renal failure secondary to thrombotic complications of suprarenal inferior vena cava filter in cancer patients. Cardiovasc Intervent Radiol 2001; 24:257-9. [PMID: 11779016 DOI: 10.1007/s00270-001-0015-9] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
PURPOSE To evaluate renal function before and after suprarenal inferior vena cava (IVC) filter placement. METHODS We describe, in a personal series of 13 consecutive cases (all of them stage IV cancer patients, one LGM filter, one Antheor filter, 11 Greenfield filters) in our institution, two cases of fatal renal vein thrombosis after placement of a suprarenal filter. Evaluation of renal function was based on serum urea (in mmol/L; normal 3.30-6.60), serum creatinine (in micromol/L; normal <115.1), and calculation of serum creatinine clearance. RESULTS AND CONCLUSION This study suggests that in advanced-stage cancer patients who have a single functional kidney, renal functional insufficiency, or previous renal vein thrombosis, IVC filter placement above the renal veins may not be appropriate. Suprarenal filter placement should be performed only after analysis of predicted survival, after detailed discussions with the patient, and most importantly after renal function evaluation.
Collapse
Affiliation(s)
- P Y Marcy
- Division of Vascular and Interventional Radiology, Centre Antoine-Lacassagne, Nice, France.
| | | | | | | |
Collapse
|
39
|
Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer 2001; 88:701-7. [PMID: 11495824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
One hundred forty-four patients with breast cancer and osteolytic bone metastases were randomized to receive either oral clodronate 1,600 mg/d (73 patients) or placebo (71 patients), in addition to either chemotherapy or hormonal therapy, for up to 12 months. Patients were withdrawn from the study when the 12 months of treatment had been achieve or a new bone event occurred, which was defined as: hypercalcemia (> 3 mmol/l), increase in, or onset of new bone pain due to metastases, requirement of radiotherapy for bone pain relief, pathological fractures (including vertebral collapse, spinal cord compression) or death due to bone metastases. Patients are well balanced according to age, performance status, bone condition, except for fractures, more frequent in the clodronate group (25% vs 12%). Of the 137 evaluable patients, 69 received oral clodronate and 68 placebo. Clodronate significantly delayed the median time to onset of new bone events compared to placebo, respectively 244 days and 180 days (p = 0.05). Hypercalcemia did not occur in the clodronate group but was observed in four placebo-treated patients. Clodronate-treated patients had a significant reduction in pain intensity compared to placebo (p = 0.01; measured using a visual pain scale) and significantly fewer patients receiving clodronate required analgesics (p = 0.02). The evaluation of global efficacy by physicians and patients indicated that clodronate was more efficacious than placebo (respectively p = 0.02 and p = 0.01). No significant difference in incidence of adverse effects was observed between the two groups. Clodronate therapy significantly delayed the occurrence of new bone events in these patients with bone metastases from breast cancer and adds to treatment of malignant osteolysis.
Collapse
Affiliation(s)
- M Tubiana-Hulin
- Service d'oncologie médicale, Centre René-Huguenin, 2, rue Gaston-Latouche, 92210 Saint-Cloud
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001; 12:217-9. [PMID: 11300327 DOI: 10.1023/a:1008331708395] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The incidence of haematologic toxicity of valproate (VPA) ranges from 1% to 32% and consists mainly of asymptomatic, dose-dependent thrombopenia. We describe a potentiation of haematologic side-effects of nitroso-urea (NU) when prescribed in association with VPA. PATIENTS AND METHODS We followed a cohort of 70 patients (58 men, 22 women, mean age: 56 years, range 20-75 years). Patients with high-grade gliomas were treated with up-front chemotherapy regimen consisting of fotemustine (d3: 100 mg/m2), cisplatin (d1-3: 33 mg/m2) and etoposide (d1-3: 75 mg/m2) followed by whole brain radiotherapy at progression. Sixty patients required anti-epileptic drugs (AED) for either a single, well-documented epileptic seizure, or immediatly initiated after neurosurgical procedures. AED included VPA (35 of 60), phenobarbital (PB) (17 of 60), carbamazepine (CBZ) (2 of 60) and phenytoin (PHT) (3 of 60). Two patients had both PB and CBZ and one PB and PHT. RESULTS Haematologic toxicity (grade 3-4 thrombopenia, neutropenia or both) was observed in 37 of 70 (52.85%) patients. Among them 24 (65%) had VPA. Group C were patients treated with fotemustine alone with or without VPA (23 patients). CONCLUSION When prescribed in association with a fotemustine-cisplatin regimen, VPA treatment results in a three-fold higher incidence of reversible thrombopenia, neutropenia or both. Haematologic side-effects decrease after AED modification during the continued chemotherapy. This adverse event should be managed with caution.
Collapse
Affiliation(s)
- V Bourg
- Service de Neurologie, H pital Pasteur, Nice, France
| | | | | | | | | |
Collapse
|
41
|
Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, Netter-Pinon G, Frenay M, Gousset C, Marié FN, Benmiloud M, Sturtz F. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000; 11:1471-6. [PMID: 11142488 DOI: 10.1023/a:1026556119020] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Verapamil (VER), a potent calcium channel blocker, has been found to overcome P-gp-mediated multi-drug resistance (MDR) and to increase sensitivity to cytotoxic anticancer drugs in refractory myeloma and non-Hodgkin lymphoma. The value of VER for treating solid tumors is still a matter for debate. PATIENTS AND METHODS We performed a prospective study in 99 patients with anthracycline-resistant metastatic breast carcinoma (MBC), to assess the clinical effect of oral VER given in association with chemotherapy. Instead of retreating patients with anthracycline, we used a partially noncross-resistant regimen (VF), combining vindesine (VDS) and 5-fluorouracil given as a continuous infusion (5-FU CI). Patients were randomly assigned to two cohorts. One cohort (47 patients) was treated in 28-day cycles, each involving the administration of VDS (3 mg/m2 i.v. bolus on days 1 and 10) and 5-FU CI, (400 mg/m2/day i.v. from day 1 to day 10). The other cohort (52 patients) received the same VDS and 5-FU treatment and an additional oral VER treatment (240 mg/day divided in 2 doses), from day 1 to day 28 of each cycle. Patients were treated until progression. RESULTS The treatment was well tolerated and no side effects that could be attributed to VER were detected. Patients treated with VER had longer overall survival (OS) (median OS: 323 vs. 209 days, P = 0.036) and a higher response rate (27% vs. 11%, P = 0.04) than those not given VER. Progression-free survival (PFS) was also longer but the difference was not statistically significant (median PFS: 4.6 and 2.7 months for the VER and non-VER groups respectively, P = 0.6). CONCLUSIONS This clinical trial demonstrates that a chemosensitizer, such as VER, can increase the survival of MBC patients with acquired anthracycline resistance.
Collapse
Affiliation(s)
- D Belpomme
- Oncology Department, H pital Boucicaut, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Frenay M, Lebrun C, Lonjon M, Bondiau PY, Chatel M. Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. Eur J Cancer 2000; 36:1026-31. [PMID: 10885607 DOI: 10.1016/s0959-8049(00)00048-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Despite combinations of surgery, radiotherapy (RT) and chemotherapy used in the treatment of glioblastomas, mean and median survival rates in most patients remain 12 months or less after diagnosis. RT and nitrosourea after surgery are the standard combination for glioblastomas. They may induce acquired resistance and, consequently, non-operable glioblastomas is a unique biological and clinical situation allowing evaluation of intrinsic chemosensitivity. We assess the fotemustine (F) (100 mg/m2 day 1)/ cisplatin (CDDP) (33 mg/m2 days 1-3)/etoposide (VP16) (75 mg/m2 days 1-3) monthly regimen for efficacy in non-removable glioblastomas at presentation. Between 1995 and 1998, 33 consecutive patients with symptomatic non-removable histologically proven glioblastomas were treated: none of them had previously received chemotherapy, irradiation or surgical debulking. Objective response was evaluated by contrast enhancement with magnetic resonance imaging (MRI) scan after each treatment. Toxicity was moderate and mainly haematological (grade III-IV thrombopenia = 20/171 cycles; leucopenia = 25/171). Neutropenic fever was rare and no intracranial haemorrhages or treatment-related deaths were noted. Nausea and vomiting (grade 1), and asymptomatic hearing loss were common. Peripheral neuropathy occurred in 3 patients. Objective response rates were 9/33 (27%) (stabilisation = 17/33). Mean survival time was 14.4 (11.2 months in the 26 deceased patients) with a median survival of 10 months. Median survival rates at 6 and 12 months were 88% and 42%, respectively. 7/33 patients are still alive with median survival of 34.6 months. 7/33 (4/7 alive) were long-term survivors (range: 19-67 months). Neoadjuvant chemotherapy in non-resectable patients is safe allowing delayed RT. Phase II chemotherapy trials should include studies with a subgroup of non-resectable tumours.
Collapse
Affiliation(s)
- M Frenay
- Centre de Lutte Contre Le Cancer Antoine Lacassagne, Nice, France
| | | | | | | | | |
Collapse
|
43
|
Frenay M, Lebrun C, Lonjon M, Marcy PY, Paquis P. [Chemotherapy of malignant inoperable gliomas. The association of fotemustine-cisplatine-etoposide as neoadjuvants]. Rev Neurol (Paris) 2000; 156:53-8. [PMID: 10693259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Efficiency of chemotherapy (CT) on non removable HGG has not been proven and neoadjuvant brain irradiation (RT) following biopsy is the standard treatment. We aimed to define whether combination of polychemotherapy and radiotherapy is synergistic in non removable HGG. It has been proven that F, CDDP and VP16 can reach therapeutic levels in brain after intravenous standard dose injections. The aim of this study was to assess that (i) neoadjuvant CT is safe; (ii) feasibility and efficacions of F (100 mg/m2.d1)/CDDP (100 mg/m2.d1-3 TD)/VP16 (75 mg/m2.d1-3) q21-28d regimen; (iii) Delayed RT is not unsafe: RT was performed when tumor progression or toxicity appeared. This study included 16 patients with symptomatic non removable HGG. Two of them had anaplastic gliomas and 14 glioblastomas multiforme. None of them had a prior chemotherapy regimen. Objective response was evaluated with CT scan or MRI during chemotherapy. Toxicity was moderate and mainly hematological (grade III-IV thrombopenia = 10/67 cycles; leukopenia = 13/67). Objective response rates were 5/16 (31 p. 100) (CR = 1; PR = 4; Median duration of response: 20 weeks). Median survival was 55 weeks in the 14 grade IV patients. Three/16 patients are still alived with respectively 22, 30, 40 months survival: These results confirm the neoadjuvant chemotherapy efficacy. It may be a useful tool before RT for non removable HGG.
Collapse
Affiliation(s)
- M Frenay
- Centre de lutte contre le cancer Antoine Lacassagne, Nice
| | | | | | | | | |
Collapse
|
44
|
Abstract
BACKGROUND No case of leukoencephalopathy has been reported associated with multiple myeloma. PATIENTS We report on two patients with a very rare association of leukoencephalopathy and multiple myeloma revealed by cognitive impairment. RESULTS Chemotherapy has improved neurological and biological signs. Radiological abnormalities have been stabilized. CONCLUSION The authors suggest that leukoencephalopathy is probably a direct cerebral expression of malignant gammopathy.
Collapse
Affiliation(s)
- C Lebrun
- Service de Neurologie, Hôpital Pasteur, Nice, France
| | | | | | | |
Collapse
|
45
|
Abstract
INTRODUCTION Neurotoxicity can be induced by the synergistic or additive effects of cytotoxic treatments, and nervous system exposure is related to routes and doses. CURRENT KNOWLEDGE AND KEY POINTS The improvements in treating systemic malignancy have been accompanied by reports of neurologic toxicity, which has an important impact on the quality of life and may even limit the use of the treatment. PERSPECTIVES AND FUTURE PROJECTS It demands out a continuous clinical evaluation to detect their appearance. When neurological complications are diagnosed later, they are rarely reversible. Neuroprotective agents are still being evaluated.
Collapse
Affiliation(s)
- C Lebrun
- Service de neurologie, CHU, Nice, France
| | | | | |
Collapse
|
46
|
Rochet N, Dubousset J, Mazeau C, Zanghellini E, Farges MF, de Novion HS, Chompret A, Delpech B, Cattan N, Frenay M, Gioanni J. Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). Int J Cancer 1999; 82:282-5. [PMID: 10389764 DOI: 10.1002/(sici)1097-0215(19990719)82:2<282::aid-ijc20>3.0.co;2-r] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Permanent human osteosarcoma cell lines are important tools for the study of bone cancer. As representative of an osteoblastic phenotype, they partly reflect their normal osteoblastic counterparts and, thus, may represent appropriate models to investigate the mechanisms involved in bone remodelling and in haematopoietic differentiation. In the present work, we describe a new human cell line, CAL 72, obtained from an osteosarcoma of the knee of a 10-year-old boy. These cells grow in continuous culture, and karyotypic analysis has revealed clonal abnormalities in number and structure, especially loss of chromosome Y. These cells exhibit morphological, immuno-histochemical and molecular characteristics of the osteoblastic lineage. Using RT-PCR, we have shown that the CAL 72 cell line expresses high levels of mRNA coding for several cytokines, such as G-CSF, GM-CSF, IL-1beta and IL-6. In view of this expression profile, the CAL 72 phenotype appears to be closer to normal primary osteoblasts than other reported osteosarcomas. Moreover, these cells express mRNA for both HGF and its receptor c-MET, suggesting that this autocrine loop might contribute to the invasiveness of the tumour from which CAL 72 originated.
Collapse
Affiliation(s)
- N Rochet
- INSERM U364, Faculté de Médecine, Nice, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Lebrun C, Frenay M, Lonjon M, Marcy PY, Grellier P. [Brain metastases and chemotherapy]. Rev Med Interne 1999; 20:247-52. [PMID: 10216881 DOI: 10.1016/s0248-8663(99)83052-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION The epidemiology of brain or central nervous system metastases is poorly documented. Retrospective studies based on autopsies that were aimed at investigating the incidence and prevalence of brain metastases have revealed the shortfalls in tumour registers. The exact role of cerebral metastases has not been addressed within the scope of cancer considered as a public health issue. CURRENT KNOWLEDGE AND KEY POINTS The prognosis of brain metastases should not be considered either on general or a priori basis as being poorer than that of other metastatic sites. Evaluation of the role of focal radiation therapy and chemotherapy is still in progress. Appropriate use of therapeutical strategies directed at brain tumors generally improves the condition of most patients. It also usually increases survival and enhances the quality of life. FUTURE PROSPECTS AND PROJECTS The role of chemotherapy in current therapeutical strategies has not yet been defined and should be investigated and developed.
Collapse
Affiliation(s)
- C Lebrun
- Service de neurologie, hôpital Pasteur, CHU, Nice, France
| | | | | | | | | |
Collapse
|
48
|
Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M, Grellier P, Frenay M, Milano G. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998; 4:2383-90. [PMID: 9796969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The aim of this study was to perform a multivariate analysis including clinical and biological prognostic factors on glial tumor outcome. Seventy-nine patients were analyzed (48 men and 31 women; mean age = 56 years, range = 16-77 years): 7 had a benign glial tumor (grades 1 and 2), 21 had an anaplastic glial tumor (grade 3), and 51 had a glioblastoma (grade 4). Median follow-up was 17.9 months for patients who survived (50 patients died). Biopsies were obtained at time of diagnosis (complete tumor resection in 62 patients and stereotaxic biopsies in 17 patients). Epidermal growth factor receptor (EGFR) was measured by a binding assay, and labeling index (LI) was measured by tritiated thymidine incorporation. EGFR varied from 4 to 73,110 fmol/mg protein (mean = 3912 fmol/mg protein; median = 374 fmol/mg protein; n = 79). LI varied between 0.1 and 16.5% (mean = 6.2%; median = 5.2%; n = 40). Log10 EGFR was significantly and positively correlated with patient age. LI was significantly different according to tumor histology. Univariate Cox analysis (end point was cancer death) showed that age (P = 0.027), log10 EGFR (P = 0.025), and LI (P = 0.0019) were significant continuous variables, the survival being shortened when the covariable increased; tumor resection (P = 0.015, relative risk = 0.45) and histology (P = 0.0009) were significant categorical factors. A multivariate Cox analysis (forward selection) including age, histology, tumor resection, log10 EGFR, and LI revealed that log10 EGFR, LI, and tumor resection were the only independent significant predictors of survival. This multivariate approach reveals that the clinical prognostic factors of glial tumors, namely age and tumor histology, disappear, to the benefit of intrinsic characteristics of the tumor, i.e., EGFR expression and LI, suggesting that coupled EGFR and LI determination could be a useful tool for better evaluation of glial tumor outcome.
Collapse
|
49
|
Abstract
INTRODUCTION Seizures are common in patients presenting with intracranial tumors. Nevertheless, the incidence of cancer is not higher in patients with seizures. We attempted to summarize situations that can lead to the diagnosis or treatment of seizures in patients presenting with cancer. CURRENT KNOWLEDGE AND KEY POINTS Focal neurological signs on clinical examination when seizures occur for the first time in patients with cancer lead to brain imaging. As a result of recent advances in neuro-imaging techniques, the presence of a tumor is now more frequently observed in patients with seizures. PERSPECTIVES AND FUTURE PROJECTS As it may have irritating effects on the cerebral cortex, chemotherapy is able to either increase or induce seizures in patients presenting with cancer. Potential pharmacological interactions between antiepileptic and cytotoxic drugs thus require close surveillance in patients with cancer.
Collapse
Affiliation(s)
- C Lebrun
- Service de neurologie, Hôpital Pasteur, Nice, France
| | | | | | | |
Collapse
|
50
|
Lebrun C, Chichmanian RM, Peyrade F, Chatel M, Frenay M. Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: a previously unknown adverse event. Ann Oncol 1997; 8:919-20. [PMID: 9358948 DOI: 10.1023/a:1008205308867] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|